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ABSTRACT 
Nanoparticles (NPs) functionalized with targeting ligands are expected to improve the yield 
of targeted drug delivery by recognizing target cells and selectively delivering the therapeutic 
drugs to these cells. However, functionalized-NPs often have low targeting efficiency when they 
are administered in vivo. One of the major causes of this unfavorable outcome is that proteins 
and other biomolecules adsorb onto the particles upon NPs’ injection into the blood stream, and 
form a biological coating named “protein corona.” Protein corona formation could remarkably 
affect NPs’ blood circulation, their cellular uptake, and targeting efficiency. Because current 
methods, such as PEGylation, could not fully resolve this issue, we aimed to address this 
challenge by exploiting the protein corona itself instead for targeted NP delivery. Here, we used 
the well-established opsonin-mediated phagocytosis of NPs to investigate if it is feasible to form 
an opsonin-enriched corona that actively targets NPs to immune cells by pre-coating NPs with 
gamma-globulins to promote the adsorption of opsonins (i.e. immunoglobulins) onto the NPs. 
Our results showed that while the corona of the gamma-globulin pre-coated NPs became 
enriched with opsonins upon incubation with human plasma, this enrichment did not enhance 
NP uptake by the target immune cells. Evaluation of the accessibility of immunoglobulins in the 
opsonin-enriched protein corona indicated that these proteins were not able to interact with their 
target biomolecules due to the screening effect of the other plasma proteins in the corona. 
Therefore, it is essential to control the spatial location of targeting proteins in the corona in order 
to form a functional corona for targeted NP delivery. 
In this work to exploit the protein corona for targeted NP delivery, the NPs were incubated 
with human plasma in vitro to mimic protein corona formation in the blood stream. However, 
other biological mediums, such as human serum, could be used in vitro for protein corona 
formation. The effect of these solutions, human serum or human plasma, on the corona’s 
composition and NP’s interactions with biological systems had not been thoroughly investigated. 
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To address this issue, we exposed NPs to human serum and human plasma solutions and 
assessed the differences in these two protein coronas, and whether they affected NP uptake by 
cells. Our study demonstrates that NPs exposed to human plasma have larger diameters, more 
bound proteins, and more opsonins (e.g. fibrinogen) in their coronas than serum-exposed NPs. 
The presence of more opsonins in the coronas of the plasma-exposed NPs resulted in higher 
macrophage uptake of these particles than NPs exposed to human serum. Because, these two 
biological solutions yield protein coronas with different compositions, and human plasma better 
mimics the protein composition in the blood stream, human plasma should be utilized for in vitro 
protein corona studies.  
A challenge in the area of regenerative medicine was also addressed. Artificial cell cultures 
have been developed to identify the factors that direct hematopoietic stem cells (HSCs) to 
differentiate into specific lineages. Due to the rarity of stem cells, the number of HSCs utilized in 
these cultures must be minimized. However, HSC populations exhibit high cell-to-cell 
heterogeneity, so the culture must contain enough cells to elicit the full range of fate decisions 
found in the body. This creates a need for new tools for characterizing the heterogeneity of HSC 
populations. Here, we show the heterogeneity between and within hematopoietic cell 
populations can be visualized by developing self organizing map (SOM) models of time-of-flight 
secondary ion mass spectrometry data that contains information about biomolecules on the 
surfaces of these cells. The SOM models developed for B cells, common lymphoid progenitors 
(CLPs), and hematopoietic stem and progenitor cells (HSPCs) suggested that B cells are the 
least heterogeneous and the CLPs are the most heterogeneous of these three hematopoietic 
cell populations. 
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CHAPTER 1 
INTRODUCTION  
1.1 Nanoparticles as Vehicles for Drug Delivery 
Recent advances in drug discovery and pharmaceutical sciences have led to the synthesis 
and production of potent therapeutic drugs with improved biological activity. However, in 
addition to the therapeutic activity of the drug against the target disease or pathogen, other key 
factors may significantly affect a drug’s performance in disease treatment, such as its water 
solubility and body circulation time.1 Moreover, the non-targeted delivery of toxic pharmaceutical 
drugs to healthy cells and tissues in the body as well as the diseased cells often results in 
severe side effects. For example, nausea, hair loss, and blood disorders are some of the 
common side effects of the chemotherapeutic reagents that are used as anticancer therapies. 
The non-controlled release of these pharmaceutical drugs also necessitates multiple drug 
administrations, which reduces the likelihood that a patient will adhere to their treatment 
schedule.2 Such non-compliance is detrimental to patient health. Hence, novel drug delivery 
methods that address these problems could remarkably improve the efficacy of current 
therapeutic drug treatments. 
During the last decades, nanotechnology has been applied in various scientific fields, 
including medicine and biotechnology. For instance, nanoparticles (NPs) with a size range of 1-
100 nm have been recognized as promising drug carrier systems that could enhance drug 
circulation time and bioavailability within the human body. Due to their high surface area to 
volume ratio, NPs have a great capacity to adsorb biomolecules and therapeutic compounds 
and transport them to the desired cells and organs. In addition, their small size, which is similar 
to cellular components such as proteins and cell membranes, allows the NPs to circulate in the 
blood stream without causing an embolism, and also promotes more efficient cellular uptake 
than larger particles.3 The NP formulation can be engineered in order to control payload release 
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kinetics, which could help to maintain a constant drug concentration within the target tissue 
environment.3–5 This controlled release would reduce the number of NP treatments that must be 
administered to the patient, and improve patient compliance. The main nano-vehicles that have 
been applied for drug delivery applications are inorganic NPs (e.g. SiO2, metal, and magnetic 
NPs), polymeric NPs, carbon-based NPs, and lipid-based NPs. These diverse NP compositions 
render NPs useful for other medical applications, such as disease diagnosis. For example, 
magnetic iron oxide NPs have been used to improve contrast in magnetic resonance imaging 
(MRI).6           
1.2 Cancer Treatment via NP Targeted Drug Delivery 
As discussed above, a main goal of NP-based drug delivery systems is to selectively 
transport therapeutic reagents to a desired location in the body in order to decrease the 
cytotoxic side effects of these drugs towards healthy cells and organs. This selective delivery of 
the therapeutic payload to the disease site could also reduce the quantity of drug that is 
required for disease treatment. Thus, targeted NP delivery methods have been applied to 
selectively carry chemotherapeutic drugs to cancer cells in order to reduce their devastating 
side effects.  
There are two approaches for targeting NPs to the tumor tissue and cancer cells. The first 
approach is the passive targeting of NPs to the tumor microenvironment based on the enhanced 
permeability and retention (EPR) effect.7–9 Tumor tissue has a leaky vasculature to due to 
defects in blood vessel structure within the tumor environment. Consequently, particles with 
diameters less than 100 nm may  penetrate into the tumor tissue through this leaky vasculature, 
causing the NPs to accumulate in the tumor.8 However, the increase in interstitial fluid pressure 
that often occurs in tumor tissue can prevent the NPs from entering the tumor and delivering 
their therapeutic cargo to the cancer cells.10 In addition, some tumor tissues might not have a 
permeable vasculature that can be exploited for passive targeting.7,10 The second NP-based 
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delivery approach involves active targeting. In this approach, the surfaces of the NPs are 
functionalized with various biomolecules and compounds, such as aptamers or antibodies, that 
selectively bind to cancer cells, but not to healthy cells. The binding of these targeting ligands to 
the receptors or biomolecules in the plasma membranes of the cancer cells induces NP uptake 
by endocytosis.11,12  
   While functionalized NPs present significant targeting capabilities in vitro, their targeting 
capabilities are much lower in vivo.13,14 For example, the targeting efficiencies of functionalized 
NPs that are designed to selectively deliver anticancer drugs to tumor cells are frequently below 
10% in vivo.15 A major cause of this poor performance in vivo is that the binding of plasma 
proteins to the NPs’ surfaces promotes their recognition by immune cells and clearance by the 
mononuclear phagocyte system (MPS).16  
1.3 The Protein Corona is Detrimental to Nanoparticle-Based Targeted Drug Delivery 
When NPs enter the biological environment (e.g. the blood stream), proteins and other 
biomolecules rapidly bind to their surfaces, forming a layer known as the “protein corona” (Fig. 
1.1).15,17,18 The protein corona consists of two protein layers. The inner layer, or “hard corona”, is 
composed of strongly bound proteins that slowly exchange with free proteins in the 
environment. The outer layer, or “soft corona”, contains weakly bound and rapidly exchanging 
proteins.13 Thus, the protein corona has a dynamic structure in which high abundance, low 
affinity proteins are replaced by proteins with low abundance but high affinity. NP properties, 
such as chemical composition, size, and surface charge, greatly affect protein corona 
composition,19,20 whereas the bound proteins in turn, influence NP biodistribution,19,21,22 targeting 
efficiency,14,23 and cellular uptake.24–27     
The binding of certain plasma proteins, namely opsonins, to foreign particles in the body 
enhances the detection of these particles by the immune system, and their elimination from the 
body.13,19 Thus, the binding of opsonins, such as fibrinogen, immunoglobulins, and complement 
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factors, to the NPs would reduce their circulation time, and consequently, decrease the fraction 
of NPs that reach the diseased tissue.13,19  In contrast to opsonins, the binding of dysopsonins, 
such as albumin, enhances NP circulation time within the body.13,19,28 Thus, the identity of 
proteins in the corona may greatly influence their biodistribution and biological fate. 
As part of my M.S. thesis research, I demonstrated that the protein corona could reduce the 
targeting capabilities of functionalized NPs via a non-biological mechanism by covering the 
targeting ligands and preventing them from interacting with their target molecules.14 In that 
study, I designed a cell-free targeting approach based on copper-free click reaction between 
fluorescent silica NPs functionalized with a strained cycloalkyne group, bicyclononyne (BCN) 
and an azide group on a silicon substrate to explore the effect of protein corona on NPs’ 
targeting yield (Scheme 1.1). First, I prepared BCN-functionalized NPs (BCN-NPs) and azide-
modified substrates, followed by exposing BCN-NPs to the biological fluids to form the protein 
corona. Next, I incubated protein coated functionalized NPs (corona-BCN-NPs) and corona-free 
functionalized NPs (BCN-NPs) with the azide-modified substrates to assess whether the protein 
corona compromised NP conjugation to the substrate. Fluorescence microscopy images 
demonstrated that upon incubation of BCN-NPs with serum proteins and protein corona 
formation, these NPs were not capable of binding to the azide-modified silicon substrate due to 
the screening effect of adsorbed proteins (Fig. 1.2).  
Others have also shown that the protein corona reduces NPs’ targeting efficiency by 
screening the targeting ligands.23 The adsorption of high molecular weight plasma proteins 
significantly reduced the binding of poly(lactide-co-glycolic-acid) (PLGA) particles that were 
functionalized for vascular targeting to the endothelial cells.29 The protein corona may also 
decrease NP uptake by the desired cells by reducing NP adhesion to the cell membrane,27 
which decreases subsequent endocytosis of the NPs. Thus, the plasma proteins adsorbed onto 
the NPs’ surfaces strongly influences the interactions between the NPs and biological systems. 
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1.4 Strategies to Address the Detrimental Effects of Protein Corona Formation 
To reduce protein adsorption onto NPs and improve their targeting efficiency, the NPs’ 
surfaces are often modified with hydrophilic polymers, such as polyethylene glycol (PEG). 
Additionally, the PEG linker increases the distance between the NP and its targeting ligand, 
providing the ligand with more flexibility to interact with its target molecule on the cell surface. 
PEGylation reduces protein binding to the NPs. However, it does not completely prevent the 
protein adsorption.30,31 Although the adsorption of opsonins, such as immunoglobulins and 
complement factors, is supposed to be reduced by PEGylation, these opsonins were still 
detected on the surface of PEGylated liposomes, and their abundance increased as the length 
of PEG molecule increased.31   
Because PEGylation does not solve the protein corona problem, an alternative approach is 
to turn this challenge into an opportunity by exploiting the protein corona for targeted NP 
delivery.32 In this approach, corona components that have a high binding affinity to receptors on 
the desired cells are used to target the NPs to those intended cells. The abundance of these 
proteins with natural targeting abilities within the protein corona might be improved by 
engineering the NPs’ physical and chemical properties to increase the recruitment of these 
desired targeting proteins from the biological environment. A few studies have employed this 
approach,33,34 but the possibility of utilizing the proteins in the NP’s corona for targeted NP 
delivery needs to be explored further. In Chapter 2, the feasibility of engineering the protein 
corona for directing NP delivery to specific cell types is explored.  
1.5 In vitro Protein Corona Analysis      
Prediction of NPs’ interactions with plasma proteins before performing in vivo experiments 
could provide useful information regarding the bio-nano interface such as protein corona 
composition, the most abundant proteins in the corona, and the extent of NP cellular uptake or 
drug release profile in the presence of a corona. For this purpose, NPs are incubated with 
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biological mediums (e.g. human serum and human plasma) in vitro, and the chemical and 
physical properties of the corona-coated NPs and their interactions with cultured cells are 
characterized.24,27,35,36 These in vitro studies also enabled investigating how different variables, 
such as surface charge or NP size and incubation time, affect protein adsorption.37–39 For 
example, it was shown that increasing the size of silver NPs resulted in more protein binding to 
the particles, suggesting a direct correlation between particle size and the amount of adsorbed 
proteins.38 Exploring the effect of incubation time on protein corona formation indicated that 
exposure time remarkably affects the amount of proteins bound to the NPs, while it does not 
change the corona composition.39 The most common methods to characterize the protein 
corona composition and identify the adsorbed proteins are gel electrophoresis and liquid 
chromatography-mass spectrometry.      
Because the results of these in vitro investigations are used to predict the NPs’ interactions 
with biological systems in vivo (e.g. human blood), the biological mediums used for in vitro 
studies must accurately mimic the in vivo protein milieu. Human serum and human plasma are 
the most widely used biological mediums for in vitro studies of protein corona formation. 
However, these two biological milieus have considerably different compositions40 that could 
influence the composition of NP corona or its interaction with immune cells. Comprehensive 
analysis of protein coronas that are obtained by NP incubation with these two mediums would 
help to identify the proper biological environment for future in vitro experiments. In Chapter 3, 
the compositions of the protein coronas that form on NPs exposed to human serum and human 
plasma are analyzed, and the cell responses that they elicit are compared.  
1.6 Studying the Heterogeneity within Hematopoietic Cell (HC) Populations 
Though investigating the effects of the protein corona on targeted drug delivery are the 
main focus of this thesis, a portion addresses investigating the cell to cell heterogeneity within 
distinct hematopoietic cell (HC) populations at various stages of maturation.  
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Hematopoietic stem cells (HSCs) that are located in the bone marrow self-renew and 
differentiate into more mature hematopoietic cell populations.41–44 This stepwise and highly 
regulated differentiation process ultimately generates mature blood and immune cell lineages. 
The ability to direct HSCs in cultures to self-renew or differentiate into specific HC populations 
would enable expanding desired types of blood and immune cells for hematopoietic disease 
treatment and stem cell therapy.45  Due to the rarity of HSCs in the body,46 artificial micro-
cultures that minimize the number of HSCs required to screen the effects of stimuli (i.e. growth 
factors) on HSCs’ fate decisions have been developed.47–49 However HSC subpopulations 
exhibit high cell to cell heterogeneity,50 so the full spectrum of HSCs’ fate decisions that occurs 
in vivo and the complete range of their responses to the stimuli would only be observed if the 
artificial micro-culture contains a sufficient number of HSCs to recapitulate their native 
heterogeneity. So a better understanding of the extent of this within-population heterogeneity is 
required to design more efficient artificial culture systems for HSCs. 
Fritsz et al. have previously demonstrated that they could identify the differentiation stage of 
single HCs by exploiting the biochemical information that is encoded in the mass spectra of 
individual HCs.51 In their study, the mass spectral maps of HCs were collected by time-of-flight 
secondary ion mass spectrometry (TOF-SIMS), followed by constructing partial least-squares 
discriminant analysis (PLS-DA) models that were used to identify the differentiation stages of 
individual HCs. Additionally, age-related differences within each HC subpopulation, including B 
cells, common lymphoid progenitors (CLPs), and hematopoietic stem and progenitor cells 
(HSPCs), were studied by constructing principal component analysis (PCA) models of TOF-
SIMS data for cells obtained from old and young mice. These PCA models suggested that all 
HC subpopulations show an age-dependent difference in the lipid to protein ratio. While this 
study explored the age-related heterogeneity within each class of HCs obtained from different 
mice by using PCA, it is essential to apply other multivariate analysis techniques that could 
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better separate samples on a 2D plot to identify the heterogeneity between and within HC 
populations that are derived from mice with same ages. 
Self organizing map (SOM) technique is a favorable approach to look at sample 
heterogeneity. A SOM is a type of artificial neural network that represents a data set with 
numerous variables on a low dimensional (e.g. 2D) map that preserves the original spatial 
distance between the samples.52,53 SOM can separate the samples on a 2D plot more clearly 
than other multivariate analysis methods, such as principal component analysis (PCA), because 
all the variables are considered when generating the SOM model.53 SOM technique can 
generate various maps for data visualization. The Unified Distance Matrix (U-Matrix) and hit 
histograms can provide useful information about samples’ heterogeneity within each class of 
samples. The U-Matrix represents the similarity between a map unit and its neighboring units. 
The hit histogram indicates the number of samples that were assigned to and located on each 
map unit. Thus, variables of the samples that are located on the same map unit have similar 
intensities. Figure 1.3 shows arbitrary U-Matrix and hit histogram that are depicted to 
demonstrate how the information about heterogeneity within each class of samples can be 
obtained from these maps. The hit histogram shows three classes and each class contains 12 
samples. Each class of samples is located within certain locations on the map. While the 
samples of the blue class are localized within fewer map units on the lower left corner of the 
map, the samples within the green group are spread on more map units on the top portion of the 
map. This would suggest that samples within blue class are more homogeneous with respect to 
green class. The map units in the U-Matrix are colored with respect to their dissimilarity to their 
neighboring units. As shown in figure 1.3, the samples within the green group demonstrate 
higher dissimilarity to their adjacent units which indicate that they are more heterogeneous 
compared to two other classes. In Chapter 4, SOMs are used to more clearly visualize the 
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magnitude of cell to cell heterogeneity within three different HC populations that differ in their 
maturation stage.  
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1.8 Figures and Schemes 
 
Figure 1.1. Adsorption of plasma proteins onto the NP’s surface forms the protein corona. 
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 Scheme 1.1. Conjugation of BCN-NPs to the azide-modified substrate through click reaction. 
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 Figure 1.2. Fluorescence microscopy images of 5 mm by 5 mm azide-modified silicon 
substrates after incubation with BCN-NPs and corona-BCN-NPs. 
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Figure 1.3. Hit histogram and U-Matrix examples that indicate the information about 
heterogeneity within each class of samples.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
 
CHAPTER 2 
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NANOPARTICLE CELLULAR UPTAKE 
 
Notes and Acknowledgements1 
This chapter was co-authored by Vahid Mirshafiee, Raehyun Kim, Soyun Park, Morteza 
Mahmoudi, and Mary L. Kraft, and originally appeared in the journal of Biomaterials.1 We thank 
Prof. Ed Roy for providing the RAW 264.7 cell line and Prof. Catherine J. Murphy for using the 
ZetaPALS instrument. Portions of this work were carried out in the Flow Cytometry and Protein 
Sciences Facility in the Roy J. Carver Biotechnology Center, and the Microscopy and Imaging 
Facility in the Carl R. Woese Institute for Genomic Biology at the University of Illinois at Urbana-
Champaign.  A portion of this work was carried out in part in the Frederick Seitz Materials 
Research Laboratory Central Research Facilities, University of Illinois. This work was partially 
supported by a 3M Corporate Fellowship (to V.M.), a Drickamer Graduate Research Fellowship 
(to R.K.), and by the Department of Chemical and Biomolecular Engineering at the University of 
Illinois, Urbana-Champaign. 
 
 
 
                                                          
1 This chapter features the work that originally appeared in: Mirshafiee, V.; Kim, R.; Park, S.; 
Mahmoudi, M.; Kraft, M. L. Impact of Protein Pre-Coating on the Protein Corona Composition 
and Nanoparticle Cellular Uptake. Biomaterials 2016, 75, 295–304.  
http://www.sciencedirect.com/science/article/pii/S0142961215008236  
Author contributions to the work are: VM prepared nanoparticles, performed nanoparticle 
characterization, LC-MS/MS data analysis, and flow cytometry, assisted with SDS-PAGE, and 
contributed to writing the manuscript. RK performed SDS-PAGE, immuno dot-blots, confocal 
fluorescence microscopy, assisted with flow cytometry, and contributed to writing the 
manuscript. SP assisted with immuno dot-blots and confocal fluorescence microscopy. MM and 
MLK planned the experiments, assisted with data interpretation, and contributed to writing the 
manuscript.   
 
22 
 
 
2.1 Introduction 
Nanoparticles (NPs) are a promising drug delivery system that may reduce the undesired 
side effects of cytotoxic anticancer drugs by selectively transporting the drug payload to the 
desired location in the body.2,3 For this purpose, targeting ligands (e.g., aptamers or antibodies) 
that can bind to surface receptors on the desired cells are often grafted onto the NPs. The 
selective binding of these targeting ligands to receptors on the surfaces of the desired cells is 
expected to enhance NP uptake by the target cells.4,5 However, NPs functionalized with 
targeting ligands often have low targeting efficiency in vivo, and  accumulate in the liver and 
spleen rather than the intended tissue.6  
One potential cause for low targeting efficiency is that proteins and other biomolecules bind 
to the NP’s surface when it is exposed to the biological environment.7,8 The resulting long-lived 
protein coating, known as the “hard” protein corona, establishes a new biointerface that affects 
the biodistribution,9–11 cellular uptake,12–17 intracellular location,12 and payload release kinetics of 
the NPs.18 Additionally, the targeting capabilities of functionalized NPs can be reduced by a 
non-biological mechanism in which the protein corona screens the targeting ligands on the NPs’ 
surface, preventing them from interacting with their intended targets on the cell surface.19–21 To 
address this obstacle, flexible hydrophilic polymers, such as polyethylene glycol (PEG), are 
often grafted onto NPs to reduce plasma protein adsorption, or used as flexible linkers that may 
allow the targeting ligands to reach their intended receptors on the cell surface. However, 
PEGylation decreases, but does not completely prevent protein binding.22,23 Moreover, 
adsorbed proteins can screen the NP’s targeting ligands even when they are attached to a PEG 
linker.20  
An emerging alternative strategy is to functionalize NPs to promote the adsorption of 
plasma components that are naturally targeted to the desired cells.24 Upon contact with the 
blood stream, these NPs are expected to acquire a protein corona that actively targets them to 
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the desired cells.  For example, polysorbate coatings that promote the adsorption of certain 
apolipoproteins in biological fluid to the NPs could enhance NP transport across the blood-brain 
barrier.25 Recently, protein adsorption has been directed to promote the formation of functional 
protein coronas that enabled active NP targeting to hepatic stellate cells26 and cancer cells.27  
Here, we explore the feasibility of engineering NPs to direct protein corona composition for 
active NP targeting. Specifically, we assessed whether the targeting capabilities of protein 
ligands recruited directly from the plasma during corona formation would be compromised by 
the non-specific adsorption of undesired plasma components.  Although NP uptake by immune 
cells is typically detrimental to targeted drug delivery, opsonin-mediated phagocytosis of NPs28–
32 provides a well-characterized testbed for assessing whether protein corona composition can 
be tuned to promote NP uptake by specific types of cells. The binding of immunoglobulins and 
activated complement factors to Fc and complement receptors on specific types of immune cells 
(i.e., macrophages) triggers particle phagocytosis.33–36 Therefore, we aimed to engineer NPs to 
promote the adsorption of opsonins, such as immunoglobulins and activated complement 
factors, onto their surfaces, and assessed whether the resulting opsonin-rich protein corona 
enhanced NP uptake by immune cells through interactions with Fc and complement receptors. 
To promote the adsorption of opsonins from biological fluids onto the NPs,37 we pre-coated NPs 
with gamma-globulins (γ-globulins) from human plasma. For comparison, another set of NPs 
were pre-coated with human serum albumin (HSA), which is known to reduce the adsorption of 
opsonins onto drug carriers38,39 and decrease their clearance from the body.40 We demonstrate 
that the coronas of the NPs that were pre-coated with γ-globulins, but not HSA, were enriched 
with immunoglobulins and complement factors in comparison to uncoated NPs. However, the 
opsonin-rich corona on the γ-globulins pre-coated NPs did not enhance NP uptake by RAW 
264.7 macrophages. Our findings suggest that other protein corona components shielded the 
immunoglobulins and complement factors in the corona from binding to their receptors on the 
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immune cells. Thus, the targeting efficiency of proteins that were recruited from the biological 
environment to the corona can be compromised by non-specific protein adsorption.  
2.2 Materials and Methods 
2.2.1 Materials 
Unless otherwise indicated, all chemicals were purchased from Sigma-Aldrich. The 
bicinchoninic acid (BCA) protein assay kit was obtained from Pierce Biotechnology, Inc. RAW 
264.7 cells were kindly provided by Prof. Ed Roy (University of Illinois at Urbana-Champaign, 
USA). 
2.2.2 Synthesis of carboxylic acid-functionalized silica NPs (UC-NPs) 
62.5 µL of tetraethyl orthosilicate (TEOS) was added to a well-mixed solution of methanol 
(1 mL), DI water (360 µL) and 80 µL concentrated ammonia (Fisher Scientific). The mixture was 
gently stirred for 2 h. Next, silica NPs were collected by centrifugation and washed thoroughly 
with ethanol and DI water. To functionalize the silica NPs with carboxylic acid moieties, 10 mg of 
silica NPs were dispersed in 1 mL of phosphate buffered saline (PBS, Lonza). 20 µL of 
carboxyethyl-silanetriol sodium salt, 25% in water (Gelest Inc.), was added to the NP solution, 
and the mixture was stirred for 4 h.41 Carboxylic acid-functionalized NPs (UC-NPs) were 
collected by centrifugation, washed with PBS and dispersed in DI water. 
2.2.3 Synthesis of fluorescent carboxylic acid-functionalized silica NPs 
 30 mg of 3-aminopropyltrimethoxysilane (APTMS) and 17 mg of rhodamine B 
isothiocyanate (RITC) were added to 1 mL of ethanol with triethylamine (20 µL), and stirred for 
12 h at 50 °C in the dark. After removing the solvent under vacuum, the crude RITC-silane was 
dissolved in methanol (10 mg/mL solution). To prepare silica NPs, tetraethyl orthosilicate (62.5 
µL) was added to the well-mixed solution of methanol (1 mL), water (360 µL) and concentrated 
ammonia (80 µL) as described above and stirred for 2 h.42 Next, 25 µL of RITC-silane solution 
was added to the mixture and the solution was gently stirred for 12 h. 20 µL of carboxyethyl-
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silanetriol sodium salt (25% in water) was added to the solution and it was further stirred for 12 
h. Finally, fluorescent carboxylic acid-functionalized NPs were collected by centrifugation, 
washed with ethanol and DI water, and dispersed in DI water. 
2.2.4 Preparation of HSA and γ-globulins pre-coated NPs (HSA-NPs and GG-NPs) 
2 mg of carboxylic acid-functionalized NPs (UC-NPs) were dispersed in 1 mL of MES buffer 
(0.1M, pH 6.8). 50 mg of each 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC) and N-hydroxy-succinimide (NHS) were added to the solution and the mixture was stirred 
for 25 min. Activated NPs were collected by centrifugation, washed with PBS, and dispersed in 
1 mL of PBS. 5 mg of pre-coating proteins (albumin from human serum or γ-globulins from 
human blood) were immediately added to NP solution and stirred for 2 h. Protein pre-coated 
NPs (HSA-NPs and GG-NPs) were collected by centrifugation and washed with PBS to remove 
unbound or loosely bound proteins. The resulting pre-coated NPs were dispersed in PBS. The 
bicinchoninic acid (BCA) protein assay was used to quantify the amount of proteins on the NPs 
following chemical conjugation. For comparison, the BCA assay was also performed on 
unactivated NPs that were exposed to γ-globulin and HSA solutions under the same conditions 
as the activated NPs.  To further assess γ-globulin conjugation to the NPs, GG-NPs were 
incubated with SDS-containing Laemmli sample buffer for 5 min, collected by centrifugation, and 
the amount of γ-globulins that remained on NPs were quantified by a BCA assay.   
2.2.5 Preparation of hard corona NPs (corona-UC-NPs, corona-HSA-NPs, and corona-GG-
NPs)  
500 µg of control (UC-NPs) and protein pre-coated NPs (HSA-NPs and GG-NPs) were 
exposed to 10% or 55% human plasma solutions (10% or 55% human plasma in PBS) and 
incubated at 37 °C for 1 h with occasional shaking. Next, NPs were collected by centrifuge and 
washed two times with cold PBS (4 °C) to remove the unbound or loosely bound proteins. SDS-
PAGE analysis of the protein corona composition obtained on each type of NP indicated that 
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adding a third washing step did not affect the composition of the hard corona. NPs with hard 
corona (corona-UC-NPs, corona-HSA-NPs, and corona-GG-NPs) were dispersed in PBS. The 
zeta-potential and hydrodynamic diameter measurements for control (UC-NPs), protein pre-
coated NPs (HSA-NPs and GG-NPs), and corona-NPs (corona-UC-NPs, corona-HSA-NPs, and 
corona-GG-NPs) were performed in PBS using a Brookhaven ZetaPALS instrument. 
2.2.6 Analysis of the sizes of the NPs using scanning electron microscopy 
UC-NPs, protein pre-coated NPs, and NPs with hard coronas were placed on 5 mm x 5 mm 
silicon substrates (Ted Pella Inc.) and coated with Au/Pd using an Emitech K575 sputter coater. 
The NPs were imaged with a Hitachi S-4800 high resolution scanning electron microscope. For 
each sample, the size of 50 NPs was measured using Image J software.    
2.2.7 Quantitative analysis of proteins bound to GG-NPs and corona-GG-NPs using BCA 
assay  
Two sets of γ-globulins pre-coated NPs (GG-NPs, 500 µg) were incubated with either PBS 
or 55 % human plasma solution at 37 °C for 1 h with occasional shaking. Next, NPs were 
collected by centrifugation and washed two times with cold PBS to remove the unbound or 
loosely bound proteins. The amounts of proteins on GG-NPs and corona-GG-NPs were 
measured with a BCA assay. 
2.2.8 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of 
hard corona  
The proteins on the NPs were denatured by heating the NPs in Laemmli sample buffer 
without mercaptoethanol (non-reducing condition) for 5-10 min at 85 °C and separated by 
electrophoresis on 4-20% polyacrylamide precast gels (Bio-Rad). The resulting gels were fixed 
in fixing solution (40% methanol, 10% acetic acid and 50% water), stained with QC Colloidal 
Coomassie Stain (Bio-Rad) overnight and destained in water for 2-3 h. Stained gels were 
imaged using Image Quant LAS4010 image analyzer (GE Healthcare).  
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2.2.9 Identifying the protein corona composition by LC-MS/MS  
NPs with hard corona were collected by centrifugation at 10,000 g for 30 min, and digested 
with MSG-Trypsin (G-Biosciences) at a ratio of 1:10 – 1:50 using a CEM Discover Microwave 
Digestor (Mathews, SC) at 55˚ C and maximum power of 60 watts for 15 min. Digested peptides 
were separated from NPs, lyophilized and resuspended in 5% acetonitrile with 0.1% formic acid 
for LC/MS. LC/MS was performed using a Thermo Dionex Ultimate RSLC3000 operating in 
nano mode at 300 µL/min with a gradient from water with 0.1% formic acid to acetonitrile with 
0.1% formic acid in 120 min. The trap column used was a Thermo Acclaim PepMap 100 (100 
µm x 2 cm) and the analytical column was a Thermo Acclaim PepMap RSLC (75 µm x 15 cm). 
Xcalibur raw file was converted by Mascot Distiller into peaklists that were submitted to an in-
house Mascot Server and searched against specific NCBI-NR protein databases.  
2.2.10 Cell culture  
The mouse macrophages (RAW 264.7 cells) were cultured in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin in a 5% CO2 incubator at 37 °C.  
2.2.11 Flow cytometry analysis to evaluate NP cellular uptake  
RAW 264.7 cells were used when they reached 50-70% confluence. The NPs were 
suspended in the media to make final concentration of 20 µg/mL immediately prior to incubation 
with cells. OptiMEM was used for experiments performed under serum-free culture condition 
and DMEM with 10% FBS was used when experiments were performed in the presence of 
serum. The cells were washed with PBS, incubated with NPs in the appropriate media for 2 or 6 
h and subjected to flow cytometry after thorough washing. The flow cytometry was performed 
with BD LSR II Flow Cytometry Analyzer using blue laser and 575/26 bandpass filter.  
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2.2.12 Immuno dot-blot assessment of ligand availability on NPs 
NPs (GG-NPs, corona-GG-NPs, and corona-UC-NPs) in PBS (250 µg/mL) were spotted 
onto pre-wetted polyvinylidene fluoride (PVDF) membrane and dried. Next, the membranes 
were blocked with 5% skim milk in PBS for 1 h on a shaker, and incubated with goat anti-human 
IgG, IgM, IgA antibody (Jackson ImmunoResearch, 109-005-064) in 1% skim milk in PBS 
overnight at 4 °C. The 1% skim milk was substituted with 10% FBS in experiments that 
assessed the γ-globulins’ ability to bind to Fc receptors on cells in the presence of medium 
containing 10% serum. Membranes were washed three times with PBS for 5 min each, 
incubated with HRP conjugated rabbit anti-goat antibody, and washed three times with PBS. 
Clarity Western ECL substrate (Bio-Rad) was applied, and the membranes were imaged with 
ImageQuant LAS 4000 Imager (GE Healthcare). 
2.2.13 Confocal fluorescence microscopy 
The cells were grown in glass-bottomed dishes (Cellvis) and used for microscopy when 
they reached 50-70% confluence. The cells were washed with PBS and incubated with the NPs 
in the same concentration as flow cytometry experiment for 2 h in OptiMEM for serum free 
condition. Next, cells were washed thoroughly with media and PBS and fixed with 4% 
paraformaldehyde for 15 min at room temperature. The NPs were visualized with LSM700 
confocal fluorescence microscope (Carl Zeiss) using 555 nm laser for excitation of NPs. To 
assess whether NP uptake was receptor mediated, RAW 264.7 cells grown on glass-bottomed 
petri dishes were incubated with NPs in OptiMEM (20 µg/mL) for 2 h, and then were washed 
with OptiMEM. The cells were fixed with 4% paraformaldehyde for 15 min at rt and 
permeabilized with 0.1% Triton-X 100 in PBS for 10 min on ice. To prevent nonspecific binding, 
the samples were blocked with Image-iT FX Signal Enhancer (Life Technologies) for 30 min at 
rt, followed by 1% BSA in PBS for 20 min at rt. Then the cells were incubated with rabbit anti-
CD64 (Santa Cruz Biotechnology, sc-15364) in 1% bovine serum albumin (BSA) in PBS 
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overnight at 4°C. After washing with 1% BSA in PBS 3 times, the samples were incubated with 
Alexa488 goat anti-rabbit IgG (Life Technologies) in 1% BSA in PBS, and washed 3 times with 
1% BSA in PBS. Cell nuclei were stained with Hoechst 33342 (Life Technologies) following 
manufacturer’s protocol for 15 min at rt. The cells were imaged with LSM700 (Carl Zeiss) using 
a 555 nm, 488 nm, and 405 nm laser for excitation of NPs, CD64, and nuclei, respectively. 
2.3 Results 
2.3.1 Synthesis of protein pre-coated NPs 
We pre-coated silica NPs with either γ-globulins from human plasma or HSA. The protein 
pre-coated silica NPs were prepared by chemically conjugating HSA or γ-globulins to carboxylic 
acid-functionalized NPs. After collecting the NPs via centrifugation and thoroughly washing 
them to remove most unbound or loosely bound proteins, the presence of the proteins on the 
NPs was verified with a bicinchoninic acid (BCA) colorimetric assay. In comparison to 
unactivated carboxylic acid-functionalized NPs that were exposed to γ-globulins and HSA, more 
proteins were detected on the γ-globulin pre-coated NPs (GG-NPs) and HSA pre-coated NPs 
(HSA-NPs) that had been activated with EDC/NHS (Fig. 2.1). Although the detection of proteins 
on the unactivated NPs demonstrates that some of the pre-coated γ-globulins may be physically 
adsorbed on the NPs, the increase in protein content following conjugation suggests that some 
fraction of the proteins were covalently attached to the GG-NPs and HSA-NPs.  To confirm that 
the γ-globulins were covalently attached to the GG-NPs, the physically bound proteins were 
desorbed from the NPs by treatment with sodium dodecyl sulfate (SDS), and the amount of 
protein that remained bound to the NPs was measured within a BCA assay. More than half of 
the γ-globulins remained on the GG-NPs following SDS treatment (Fig. 2.1). This finding 
indicates that the majority of the γ-globulins were covalently attached to the NPs.  
Characterization of the hydrodynamic diameters and zeta potentials of the uncoated 
carboxylic acid-functionalized NPs (UC-NPs), HSA pre-coated NPs (HSA-NPs), and γ-globulins 
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pre-coated NPs (GG-NPs) in PBS indicated the protein pre-coatings altered NP size, size 
distribution, and to a lesser extent, surface charge. Zeta potential measurements showed that 
the surfaces of the uncoated (control) and pre-coated NPs were negatively charge (Table 2.1), 
though both the GG-NPs and HSA-NPs were less negative than the UC-NPs. Compared to UC-
NPs, the hydrodynamic diameters of the HSA-NPs and GG-NPs increased by approximately 3.6 
and 8-fold, respectively, whereas the size distributions (PDI) of the NPs pre-coated with both 
proteins increased approximately 4-fold (Table 2.1). Previous reports indicate that these 
increases in size and PDI are due to the presence of the protein coating on the NPs, as well as 
the formation of a small number of aggregated protein-coated NPs.19,43 Therefore, NP size 
distribution was also assessed with SEM, which is less prone to overestimate NP size in the 
presence of aggregates. Analysis of SEM images (Fig. 2.2A) of 50 UC-NPs, HSA-NPs, and GG-
NPs revealed that the HSA and γ-globulin pre-coatings increased the NP size by approximately 
5 and 9 nm, respectively, and increased the formation of small NP aggregates (Fig. 2.2B, Table 
2.1).   
2.3.2 Formation of hard corona via NP incubation with human plasma 
As a model of protein corona formation in the bloodstream, UC-NPs (control), HSA-NPs, 
and GG-NPs were incubated for 1 h in human plasma solutions that mimic the protein 
concentration in vitro or in vivo (10% or 55% human plasma in PBS, respectively).8 After 
washing the NPs to remove unbound and loosely bound proteins, we also assessed how the 
protein corona changed NP surface charge and size. No significant difference in the surface 
charges of the various corona-NPs was detected. Dynamic light scattering (DLS) measurements 
in PBS indicated the HSA-NPs exposed to plasma (corona-HSA-NPs) and GG-NPs exposed to 
plasma (corona-GG-NPs) were larger than the UC-NPs exposed to plasma (corona-UC-NPs) 
(Table 2.1). However, these DLS measurements suggested that the corona-HSA-NPs and 
corona-GG-NPs were actually smaller than HSA-NPs and GG-NPs respectively. This decrease 
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in size likely reflects a decrease in particle aggregation following the formation of the protein 
corona, as SEM imaging showed that the corona-UC-NPs, corona-HSA-NPs, and corona-GG-
NPs clustered less than the UC-NPs, HSA-NPs, and GG-NPs (Fig. 2.2). Based on the SEM 
measurements, formation of the protein corona on the UC-NPs and HSA-NPs increased NP 
diameter by approximately 9 and 3 nm, respectively (Table 2.1).  However, the corona-GG-NPs 
were roughly the same size as the GG-NPs. Because SDS treatment indicated a little less than 
half of the γ-globulins were physically absorbed to the NPs, the lack of an increase in NP 
diameter following corona formation likely indicates that the noncovalently attached γ-globulins 
were exchanged for plasma proteins during corona formation.  
2.3.3 SDS-PAGE analysis of hard coronas 
Next, we assessed whether the composition of the protein corona that forms when NPs are 
exposed to biological fluids is influenced by the identities of the proteins that are used to pre-
coat the NPs. Following removal of the unbound and loosely bound proteins, the protein 
constituents in the resulting hard coronas were qualitatively analyzed by SDS-PAGE performed 
under non-reducing conditions (Fig. 2.3B). The protein profiles observed for corona-HSA-NPs, 
corona-GG-NPs, and corona-UC-NPs were fairly similar, but the intensities of the bands 
differed. The bands derived from the non-covalently bound proteins in the pre-coating (black 
stars, Fig. 2.3B) were identified by their presence in the protein pre-coated NPs that were not 
exposed to plasma (Fig. 2.3A). The remaining bands represent the plasma proteins that bound to 
the NPs during the incubation with plasma solutions. The plasma protein bands that differed in 
intensity between samples (red stars, Fig. 2.3B) were typically the most intense for the corona-
GG-NPs, which suggests that the γ-globulins pre-coating promoted protein adsorption.  
2.3.4 LC-MS/MS analysis of hard corona compositions 
The differences in the compositions of the hard protein coronas that formed on the pre-
coated and uncoated NPs were identified with liquid chromatography-mass spectrometry/mass 
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spectrometry (LC-MS/MS). For each sample, the weight percent (wt %) of each protein in the 
corona was calculated according to the following equation44:  
Protein Content (wt %) =
emPAIi × 𝑀𝑖
∑(emPAIi × 𝑀𝑖)
× 100 
where Mi and emPAIi are the molecular weight and exponentially modified protein abundance 
index, respectively, for that protein. The most abundant proteins detected in the coronas for 
each particle are listed in Table 2.2, and all identified proteins are listed in Tables 2.3 – 2.5. 
Analysis of the hard corona composition with respect to the molecular weight (MW) of the 
proteins showed a significant difference between the corona-UC-NPs (control), corona-HSA-
NPs, and the corona-GG-NPs (Fig. 2.4A). Compared to UC-NPs, the NPs pre-coated with HSA 
had a lower wt % of proteins in the corona with a MW below 30 kDa, and a higher percentage of 
proteins with a MW between 30-50 kDa. In contrast, the NPs pre-coated with γ-globulins had a 
much lower wt % of corona proteins with a MW of 30-50 kDa, and a higher wt % of proteins with 
a MW below 30 kDa or above 100 kDa. Given that the MWs of HSA and γ-globulins are 
approximately 69 kDa and <160 kDa, respectively, the MWs of the proteins used to pre-coat the 
NPs are not directly correlated with the MWs of the corona proteins.  
The compositions of the protein coronas were also assessed in terms of plasma protein 
classification (Fig. 2.4B). Compared to the corona-UC-NPs, pre-coating with HSA increased the 
abundance of lipoproteins and reduced the abundance of coagulation proteins, such as 
fibrinogen, in the protein corona. Pre-coating with γ-globulins had the opposite effect, reducing 
the wt % of lipoproteins and drastically increasing the wt % of complement factors (e.g., 
complement C3, C4A, C5, C1s, C8 subunits, C7, and C6) and immunoglobulins in the corona 
as compared to UC-NPs (Fig. 2.4B). Immunoglobulins constituted more than 40% of the 
proteins detected on the corona-GG-NPs. Based on the amounts of protein measured on GG-
NPs and corona-GG-NPs, ~55% of the immunoglobulins on the corona-GG-NPs (~22% of all 
33 
 
 
proteins on the corona-GG-NPs) were derived from the γ-globulins pre-coating, and the rest 
were recruited from the plasma. These results support our hypothesis that the γ-globulins pre-
coating promotes the recruitment of opsonins, namely immunoglobulins and complement 
components, in the plasma to the protein corona. 
2.3.5 Evaluation of cellular uptake of corona-UC-NPs, corona-GG-NPs, and GG-NPs 
Next, we investigated whether the high fraction of opsonins, namely complement 
components and immunoglobulins, recruited to the protein corona by the γ-globulins pre-coating 
could be utilized for cell-specific targeting.  The most abundant complement component in the 
protein corona, the unactivated complement C3 precursor (Table 2.5), does not bind to 
complement receptors on immune cell and trigger phagocytosis.33,45 Therefore, its enrichment in 
the corona would not enhance the uptake of the corona-GG-NPs by immune cells. However, 
immunoglobulins can bind to the Fc receptors on macrophages and induce NP 
phagocytosis.29,31,46 Thus, if the immunoglobulins in the corona were accessible, the high 
fraction of immunoglobulins detected on the corona-GG-NPs should enhance their uptake by 
immune cells with Fc receptors.  
We incubated fluorescent UC-NPs and GG-NPs with 55% human plasma for 1 h to mimic 
protein corona formation in the blood stream, and assessed their uptake by immune cells. RAW 
264.7 cells, which are derived from mouse monocyte macrophages, were selected for this 
experiment because they express immunoglobulin Fc receptors.47 To assess NP uptake, GG-
NPs that had not been exposed to plasma, corona-UC-NPs, and corona-GG-NPs were 
incubated with RAW 264.7 cells in serum free culture medium for 2 h. Noteworthy, DLS 
measurements indicated that in serum-free medium, the hydrodynamic diameters of the GG-
NPs were comparable to those in PBS, whereas the hydrodynamic diameters of the corona-UC-
NPs and corona-GG-NPs slightly increased (Table 2.6).  Confocal microscopy imaging of NP 
uptake by RAW 264.7 cells in serum-free OptiMEM suggested that significantly more GG-NPs 
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were internalized than corona-GG-NPs or corona-UC-NPs, whereas the corona-GG-NPs and 
corona-UC-NPs seemed to have similarly low levels of uptake (Fig. 2.5). Use of flow cytometry 
to more quantitatively assess uptake confirmed that the uptake of the corona-GG-NPs was not 
significantly different from that of the corona-UC-NPs (Fig. 2.6A, C). In contrast, the uptake of 
the GG-NPs that were not exposed to plasma by RAW 264.7 cells in serum-free medium was 
considerably higher than those of the corona-GG-NPs and corona-UC-NPs (Fig. 2.6A, C). 
Similar results were obtained for the corona-UC-NPs, corona-GG-NPs, and GG-NPs when the 
incubation time was increased to 6 h (Fig. 2.7). Additionally, the cellular uptake of GG-NPs in 
culture medium supplemented with 10% serum was evaluated to explore if the presence of 
serum proteins in the medium would reduce the uptake of GG-NPs. The presence of 10% 
serum in the culture medium had little effect on the uptake of pristine GG-NPs by RAW 264.7 
cells (Fig. 2.6B, C), which suggests the proteins had to be adsorbed onto the NP’s surface in 
order to reduce their uptake. Together these results suggest that protein corona formation 
prevented the immunoglobulins in the corona-GG-NPs from interacting with the Fc receptors on 
the RAW 264.7 cells and stimulating NP phagocytosis. 
2.3.6 Assessment of whether NP uptake is receptor mediated 
Finally, we investigated whether the decreased uptake of the corona-GG-NPs as compared 
to GG-NPs was because the protein corona created a steric barrier that limited the 
immunoglobulin’s ability to bind to the Fc receptors on the RAW 264.7 cells.   
We first probed whether the immunoglobulins in the hard coronas of the corona-GG-NPs 
were accessible to binding partners by using immuno-dot blot assays. Because some γ-
globulins are immunoglobulins, pristine GG-NPs served as a positive control. Corona-UC-NPs 
functioned as a negative control because the LC-MS/MS measurements indicated their coronas 
did not contain immunoglobulins.  Significantly more immunoglobulins were detected on the 
surfaces of the GG-NPs than on either of the corona-coated NPs (Fig. 2.8A). Although LC-
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MS/MS analysis demonstrated that the corona-GG-NPs contained much higher levels of 
immunoglobulins than the corona-UC-NPs, the immuno-dot blot assay detected only slightly 
more immunoglobulins on the surfaces of the corona-GG-NPs than on the corona-UC-NPs (Fig. 
2.8A). These results indicate that although the γ-globulins pre-coating recruited 
immunoglobulins to the protein corona, these immunoglobulins were unable to interact with their 
binding partners because they were blocked by other corona proteins. 
If proteins adsorb onto the NPs’ surfaces as soon as they are exposed to biological fluids, 
and this adsorption screens the immunoglobulins’ interactions with binding partners, why didn’t 
the presence of 10% serum more drastically reduce GG-NP uptake by the RAW 264.7 cells? 
One possibility is that amount of proteins that adsorbed onto the GG-NPs was insufficient to 
screen the immunoglobulins on NPs from interacting with their binding partners.  However, our 
finding that the amount of immunoglobulins detected on the surfaces of GG-NPs incubated in 
10% serum for 1 h prior to dot blotting were comparable to those of the corona-GG-NPs (Fig. 
2.8A) excludes this possibility. Another explanation is that in 10% serum, the GG-NPs bound to 
the Fc receptors on the RAW 264.7 cells and triggered internalization before serum protein 
adsorption was high enough to screen immunoglobulin binding. We performed dot blots in the 
presence of 10% serum to assess whether the immunoglobulins on the GG-NPs were able to 
interact with binding partners in solution containing 10% serum before protein adsorption 
blocked these interactions. As compared to GG-NPs that were dot blotted with standard 
blocking solution, the presence of 10% serum only slightly decreased the amount of 
immunoglobulins detected on the surface of the GG-NPs (Fig. 2.8B). This suggests that the high 
uptake of GG-NPs in the presence of 10% serum was observed because GG-NP binding to the 
Fc receptors on the RAW 264.7 cells and subsequent NP internalization occurred before serum 
protein adsorption reached sufficient levels to screen these interactions. 
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Next, we verified that the uptake of the GG-NPs was mediated by the binding of their 
immunoglobulin ligands to Fc receptors on the RAW 264.7 cells. To investigate the involvement 
of receptor-mediated endocytosis in the uptake of GG-NPs and corona-GG-NPs, we used 
fluorescence microscopy to visualize the NPs in parallel with CD64 (FcγRI), which is a Fc 
receptor with high binding affinity to IgG, in RAW 264.7 macrophage cells. Colocalization of 
CD64 with the GG-NPs as well as corona-GG-NPs was observed inside the cells, though the 
amount of CD64/NP colocalization was much greater for the GG-NPs than the corona-GG-NPs 
(Fig. 2.9). This indicates that these NPs were mainly internalized via Fc receptor-mediated 
endocytosis. In contrast to the GG-NPs, the uptake of the corona-UC-NPs was extremely low, 
and colocalization between CD64 and the corona-UC-NPs was not detected. Thus, the 
internalization of the GG-NPs and corona-GG-NPs, but not the corona-UC-NPs, involved a Fc 
receptor-mediated mechanism that was triggered by the binding of the immunoglobulins on the 
NPs’ surfaces.   
Overall, these studies indicate that despite the high abundance of immunoglobulins in the 
hard coronas of the corona-GG-NPs, these immunoglobulins could not interact with the Fc 
receptors because they were sterically shielded beneath other plasma proteins in the hard 
corona. 
2.4 Discussion 
In this chapter, we have investigated whether pre-coating NPs with selected proteins could 
be used to enrich the protein corona with specific plasma proteins that enable cell targeting. 
Here, we used opsonin-mediated phagocytosis of NPs to test the feasibility of directing corona 
formation for NP targeting.  Although much research focuses on how to prevent NP uptake by 
immune cells, opsonin-mediated phagocytosis of NPs is an ideal testbed because this form of 
phagocytosis is induced by specific interactions, namely opsonin binding to receptors on the 
immune cells,9,48 and methods to increase particle opsonization are well-established.37,49 We 
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have shown that corona composition can be manipulated by pre-coating the NPs with selected 
proteins. Compared to uncoated NPs, pre-coating NPs with the dysopsonin, HSA, reduced the 
amount of coagulation factors, particularly fibrinogen, in the protein corona. Because fibrinogen 
binding to NPs can initiate the release of inflammatory cytokines and induce an immune 
response,6,11,50 the reduction in fibrinogen binding may contribute to the prolonged circulation of 
albumin pre-coated delivery vehicles in the body.38,39 In comparison, pre-coating with γ-globulins 
significantly increased the abundance of immunoglobulins and complement factors in the 
protein corona, as no immunoglobulins and few complement components were detected in the 
coronas of the uncoated and HSA pre-coated NPs. 
Although protein binding may be affected by particle size and surface charge,8,11 the 
increased amounts of immunoglobulins and complement factors on the corona-GG-NPs are 
likely due to specific interactions between these opsonins and the pre-coated γ-globulins for the 
following reasons. First, NP size is reported to influence the quantity, but not the identities of the 
proteins bound to NPs,11 so the increased size of the GG-NPs should not have induced a 
drastic increase in the fractions of opsonins found it the protein corona. Second, the UC-NPs, 
HSA-NPs, and GG-NPs, all had negative zeta potentials, and thus, negatively charged surfaces, 
so the differences in protein composition cannot be attributed to differences in electrostatic 
interactions. Lastly, the colocalization of the Fc receptors on the RAW 264.7 cells with the GG-
NPs after internalization suggests that the γ-globulins pre-coated onto the NPs retained active 
conformations that enabled specific interactions with select binding partners. Therefore, specific 
interactions between the pre-coated γ-globulins and the immunoglobulins and complement 
factors in the plasma likely enriched the protein corona with these opsonins. 
The binding of immunoglobulins to Fc receptors on the surfaces of immune cells (i.e., RAW 
264.7 cells) triggers particle uptake by phagocytosis.29,31,46 The finding that exposing GG-NPs to 
plasma reduced their uptake to a level that was comparable to corona-UC-NPs suggests that 
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other plasma proteins, such as apolipoproteins, covered the active sites of the immunoglobulins 
in the protein corona, during protein corona formation.  We hypothesize that even the large, 
unactivated complement C3 precursor protein (MW ~ 190 kDa) may have compromised the 
uptake of the corona-GG-NPs by adsorbing on top of the immunoglobulins during corona 
formation, thereby preventing the immunoglobulins from binding to the Fc receptors on the RAW 
264.7 cells. Interestingly, a recent report in which multivariate statistical analysis was used to 
correlate protein corona fingerprint with potential for cell association indicated the complement 
C3 precursor is the most influential inhibitor of non-specific NP association with the cell 
surface.51 Thus, though cleavage of the complement C3 precursor yields activated complement 
fragments that promote particle phagocytosis by immune cells through a receptor-mediated 
mechanism,33,45 its unactivated precursor inhibits nonspecific NP uptake. 
Although GG-NP uptake by RAW 264.7 cells was severely reduced when the NPs were 
incubated in plasma before they encountered the RAW 264.7 cells, the uptake of GG-NPs was 
not impaired in the presence of 10% serum. Our dot blot assays suggested that under these 
conditions, the NP’s targeting ligands were able to bind to their cell surface receptors before 
protein adsorption was sufficient to screen the targeting ligands. An obvious implication of this 
finding is that targeted delivery is more likely to be successful when the functionalized NPs are 
exposed to biological fluids for a minimum amount of time before they encounter their intended 
targets. Furthermore, the amount of time that the NPs were exposed to biological fluids and 
whether the conditions of this exposure (i.e., temperature) mimic those in the body should be 
considered when assessing the success of targeted delivery in the presence of biological fluids.  
2.5 Conclusions 
In conclusion, we have demonstrated that pre-coating NPs with selected proteins prior to 
their exposure to the biological environment enables directing the formation of a protein corona 
that is enriched with plasma proteins that could be exploited for cell targeting. However, these 
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targeting proteins in the corona may lose their targeting capabilities if they are covered by other 
corona proteins. Thus, besides directing the protein corona formation, the spatial orientation of 
the recruited proteins in the corona must be controlled to ensure that they are still capable of 
interacting with their targets on the cell surface.  
 
 
 
 
 
 
 
 
 
 
 
 
  
40 
 
 
2.6 References 
(1)  Mirshafiee, V.; Kim, R.; Park, S.; Mahmoudi, M.; Kraft, M. L. Impact of Protein Pre-
Coating on the Protein Corona Composition and Nanoparticle Cellular Uptake. 
Biomaterials 2016, 75, 295–304. 
(2)  Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers 
as an Emerging Platform for Cancer Therapy. Nat. Nanotechnol. 2007, 2 (12), 751–760. 
(3)  Mahmoudi, M.; Sant, S.; Wang, B.; Laurent, S.; Sen, T. Superparamagnetic Iron Oxide 
Nanoparticles (SPIONs): Development, Surface Modification and Applications in 
Chemotherapy. Adv. Drug Deliv. Rev. 2011, 63 (1–2), 24–46. 
(4)  Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; 
Langer, R. Targeted Nanoparticle-Aptamer Bioconjugates for Cancer Chemotherapy in 
Vivo. Proc. Natl. Acad. Sci. 2006, 103 (16), 6315–6320. 
(5)  Gao, X.; Cui, Y.; Levenson, R. M.; Chung, L. W. K.; Nie, S. In Vivo Cancer Targeting and 
Imaging with Semiconductor Quantum Dots. Nat. Biotechnol. 2004, 22 (8), 969–976. 
(6)  Mahon, E.; Salvati, A.; Baldelli Bombelli, F.; Lynch, I.; Dawson, K. A. Designing the 
Nanoparticle–biomolecule Interface for “targeting and Therapeutic Delivery.” J. Controlled 
Release 2012, 161 (2), 164–174. 
(7)  Walczyk, D.; Bombelli, F. B.; Monopoli, M. P.; Lynch, I.; Dawson, K. A. What the Cell 
“Sees” in Bionanoscience. J. Am. Chem. Soc. 2010, 132 (16), 5761–5768. 
(8)  Mahmoudi, M.; Lynch, I.; Ejtehadi, M. R.; Monopoli, M. P.; Bombelli, F. B.; Laurent, S. 
Protein−Nanoparticle Interactions: Opportunities and Challenges. Chem. Rev. 2011, 111 
(9), 5610–5637. 
(9)  Nagayama, S.; Ogawara, K.; Fukuoka, Y.; Higaki, K.; Kimura, T. Time-Dependent 
Changes in Opsonin Amount Associated on Nanoparticles Alter Their Hepatic Uptake 
Characteristics. Int. J. Pharm. 2007, 342 (1–2), 215–221. 
41 
 
 
(10)  Furumoto, K.; Ogawara, K.; Nagayama, S.; Takakura, Y.; Hashida, M.; Higaki, K.; 
Kimura, T. Important Role of Serum Proteins Associated on the Surface of Particles in 
Their Hepatic Disposition. J. Controlled Release 2002, 83 (1), 89–96. 
(11)  Aggarwal, P.; Hall, J. B.; McLeland, C. B.; Dobrovolskaia, M. A.; McNeil, S. E. 
Nanoparticle Interaction with Plasma Proteins as It Relates to Particle Biodistribution, 
Biocompatibility and Therapeutic Efficacy. Adv. Drug Deliv. Rev. 2009, 61 (6), 428–437. 
(12)  Lesniak, A.; Fenaroli, F.; Monopoli, M. P.; Åberg, C.; Dawson, K. A.; Salvati, A. Effects of 
the Presence or Absence of a Protein Corona on Silica Nanoparticle Uptake and Impact 
on Cells. ACS Nano 2012, 6 (7), 5845–5857. 
(13)  Zhu, Y.; Li, W.; Li, Q.; Li, Y.; Li, Y.; Zhang, X.; Huang, Q. Effects of Serum Proteins on 
Intracellular Uptake and Cytotoxicity of Carbon Nanoparticles. Carbon 2009, 47 (5), 
1351–1358. 
(14)  Zhu, Z.-J.; Posati, T.; Moyano, D. F.; Tang, R.; Yan, B.; Vachet, R. W.; Rotello, V. M. The 
Interplay of Monolayer Structure and Serum Protein Interactions on the Cellular Uptake of 
Gold Nanoparticles. Small 2012, 8 (17), 2659–2663. 
(15)  Lesniak, A.; Salvati, A.; Santos-Martinez, M. J.; Radomski, M. W.; Dawson, K. A.; Åberg, 
C. Nanoparticle Adhesion to the Cell Membrane and Its Effect on Nanoparticle Uptake 
Efficiency. J. Am. Chem. Soc. 2013, 135 (4), 1438–1444. 
(16)  Fleischer, C. C.; Payne, C. K. Secondary Structure of Corona Proteins Determines the 
Cell Surface Receptors Used by Nanoparticles. J. Phys. Chem. B 2014, 118 (49), 14017–
14026. 
(17)  Qiu, Y.; Liu, Y.; Wang, L.; Xu, L.; Bai, R.; Ji, Y.; Wu, X.; Zhao, Y.; Li, Y.; Chen, C. Surface 
Chemistry and Aspect Ratio Mediated Cellular Uptake of Au Nanorods. Biomaterials 
2010, 31 (30), 7606–7619. 
42 
 
 
(18)  Cifuentes-Rius, A.; de Puig, H.; Kah, J. C. Y.; Borros, S.; Hamad-Schifferli, K. Optimizing 
the Properties of the Protein Corona Surrounding Nanoparticles for Tuning Payload 
Release. ACS Nano 2013, 7 (11), 10066–10074. 
(19)  Mirshafiee, V.; Mahmoudi, M.; Lou, K.; Cheng, J.; Kraft, M. L. Protein Corona Significantly 
Reduces Active Targeting Yield. Chem. Commun. 2013, 49 (25), 2557–2559. 
(20)  Salvati, A.; Pitek, A. S.; Monopoli, M. P.; Prapainop, K.; Bombelli, F. B.; Hristov, D. R.; 
Kelly, P. M.; Åberg, C.; Mahon, E.; Dawson, K. A. Transferrin-Functionalized 
Nanoparticles Lose Their Targeting Capabilities When a Biomolecule Corona Adsorbs on 
the Surface. Nat. Nanotechnol. 2013, 8 (2), 137–143. 
(21)  Sobczynski, D. J.; Charoenphol, P.; Heslinga, M. J.; Onyskiw, P. J.; Namdee, K.; 
Thompson, A. J.; Eniola-Adefeso, O. Plasma Protein Corona Modulates the Vascular 
Wall Interaction of Drug Carriers in a Material and Donor Specific Manner. PLoS ONE 
2014, 9 (9). 
(22)  Gref, R.; Lück, M.; Quellec, P.; Marchand, M.; Dellacherie, E.; Harnisch, S.; Blunk, T.; 
Müller, R. H. “Stealth” Corona-Core Nanoparticles Surface Modified by Polyethylene 
Glycol (PEG): Influences of the Corona (PEG Chain Length and Surface Density) and of 
the Core Composition on Phagocytic Uptake and Plasma Protein Adsorption. Colloids 
Surf. B Biointerfaces 2000, 18 (3–4), 301–313. 
(23)  Pozzi, D.; Colapicchioni, V.; Caracciolo, G.; Piovesana, S.; Capriotti, A. L.; Palchetti, S.; 
Grossi, S. D.; Riccioli, A.; Amenitsch, H.; Laganà, A. Effect of Polyethyleneglycol (PEG) 
Chain Length on the Bio–nano-Interactions between PEGylated Lipid Nanoparticles and 
Biological Fluids: From Nanostructure to Uptake in Cancer Cells. Nanoscale 2014, 6 (5), 
2782–2792. 
43 
 
 
(24)  Caracciolo, G. Liposome–protein Corona in a Physiological Environment: Challenges and 
Opportunities for Targeted Delivery of Nanomedicines. Nanomedicine Nanotechnol. Biol. 
Med. 
(25)  Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; 
Alyautdin, R. Apolipoprotein-Mediated Transport of Nanoparticle-Bound Drugs Across the 
Blood-Brain Barrier. J. Drug Target. 2002, 10 (4), 317–325. 
(26)  Zhang, Z.; Wang, C.; Zha, Y.; Hu, W.; Gao, Z.; Zang, Y.; Chen, J.; Zhang, J.; Dong, L. 
Corona-Directed Nucleic Acid Delivery into Hepatic Stellate Cells for Liver Fibrosis 
Therapy. ACS Nano 2015. 
(27)  Caracciolo, G.; Cardarelli, F.; Pozzi, D.; Salomone, F.; Maccari, G.; Bardi, G.; Capriotti, A. 
L.; Cavaliere, C.; Papi, M.; Laganà, A. Selective Targeting Capability Acquired with a 
Protein Corona Adsorbed on the Surface of 1,2-Dioleoyl-3-Trimethylammonium 
Propane/DNA Nanoparticles. ACS Appl. Mater. Interfaces 2013, 5 (24), 13171–13179. 
(28)  Benjamin E Steinberg, S. G. Analysis of Macrophage Phagocytosis: Quantitative Assays 
of Phagosome Formation and Maturation Using High-Throughput Fluorescence 
Microscopy. Methods Mol. Biol. Clifton NJ 2009, 531, 45–56. 
(29)  Sobota, A.; Strzelecka-Kiliszek, A.; Gładkowska, E.; Yoshida, K.; Mrozińska, K.; 
Kwiatkowska, K. Binding of IgG-Opsonized Particles to FcγR Is an Active Stage of 
Phagocytosis That Involves Receptor Clustering and Phosphorylation. J. Immunol. 2005, 
175 (7), 4450–4457. 
(30)  Takasaki, S.; Emling, F.; Leive, L. Variants Deficient in Phagocytosis of Latex Beads 
Isolated from the Murine Macrophagelike Cell Line J774. J. Cell Biol. 1984, 98 (6), 2198–
2203. 
(31)  Cannon, G. J.; Swanson, J. A. The Macrophage Capacity for Phagocytosis. J. Cell Sci. 
1992, 101 (4), 907–913. 
44 
 
 
(32)  Moyano, D. F.; Goldsmith, M.; Solfiell, D. J.; Landesman-Milo, D.; Miranda, O. R.; Peer, 
D.; Rotello, V. M. Nanoparticle Hydrophobicity Dictates Immune Response. J. Am. Chem. 
Soc. 2012, 134 (9), 3965–3967. 
(33)  Brown, E. J. Complement Receptors and Phagocytosis. Curr. Opin. Immunol. 1991, 3 (1), 
76–82. 
(34)  Cabec, V. L.; Carréno, S.; Moisand, A.; Bordier, C.; Maridonneau-Parini, I. Complement 
Receptor 3 (CD11b/CD18) Mediates Type I and Type II Phagocytosis During Nonopsonic 
and Opsonic Phagocytosis, Respectively. J. Immunol. 2002, 169 (4), 2003–2009. 
(35)  Daëron, M. Fc RECEPTOR BIOLOGY. Annu. Rev. Immunol. 1997, 15 (1), 203–234. 
(36)  Swanson, J. A.; Hoppe, A. D. The Coordination of Signaling during Fc Receptor-Mediated 
Phagocytosis. J. Leukoc. Biol. 2004, 76 (6), 1093–1103. 
(37)  Potter, E. V.; Stollerman, G. H. The Opsonization of Bentonite Particles by Γ-Globulin. J. 
Immunol. 1961, 87 (1), 110–118. 
(38)  Ogawara, K.; Furumoto, K.; Nagayama, S.; Minato, K.; Higaki, K.; Kai, T.; Kimura, T. Pre-
Coating with Serum Albumin Reduces Receptor-Mediated Hepatic Disposition of 
Polystyrene Nanosphere: Implications for Rational Design of Nanoparticles. J. Controlled 
Release 2004, 100 (3), 451–455. 
(39)  Furumoto, K.; Yokoe, J.-I.; Ogawara, K.; Amano, S.; Takaguchi, M.; Higaki, K.; Kai, T.; 
Kimura, T. Effect of Coupling of Albumin onto Surface of PEG Liposome on Its in Vivo 
Disposition. Int. J. Pharm. 2007, 329 (1–2), 110–116. 
(40)  Ogawara, K.; Yoshida, M.; Kubo, J.; Nishikawa, M.; Takakura, Y.; Hashida, M.; Higaki, K.; 
Kimura, T. Mechanisms of Hepatic Disposition of Polystyrene Microspheres in Rats: 
Effects of Serum Depend on the Sizes of Microspheres. J. Controlled Release 1999, 61 
(3), 241–250. 
45 
 
 
(41)  Wang, L.; Zhao, W.; O’Donoghu, M. B.; Tan, W. Fluorescent Nanoparticles for 
Multiplexed Bacteria Monitoring. Bioconjug. Chem. 2007, 18 (2), 297–301. 
(42)  Tang, L.; Fan, T. M.; Borst, L. B.; Cheng, J. Synthesis and Biological Response of Size-
Specific, Monodisperse Drug–Silica Nanoconjugates. ACS Nano 2012, 6 (5), 3954–3966. 
(43)  Shapero, K.; Fenaroli, F.; Lynch, I.; Cottell, D. C.; Salvati, A.; Dawson, K. A. Time and 
Space Resolved Uptake Study of Silica Nanoparticles by Human Cells. Mol. Biosyst. 
2011, 7 (2), 371–378. 
(44)  Ishihama, Y.; Oda, Y.; Tabata, T.; Sato, T.; Nagasu, T.; Rappsilber, J.; Mann, M. 
Exponentially Modified Protein Abundance Index (emPAI) for Estimation of Absolute 
Protein Amount in Proteomics by the Number of Sequenced Peptides per Protein. Mol. 
Cell. Proteomics 2005, 4 (9), 1265–1272. 
(45)  Van Kessel, K. P. M.; Bestebroer, J.; van Strijp, J. A. G. Neutrophil-Mediated 
Phagocytosis of Staphylococcus Aureus. Microb. Immunol. 2014, 5, 467. 
(46)  Pacheco, P.; White, D.; Sulchek, T. Effects of Microparticle Size and Fc Density on 
Macrophage Phagocytosis. PLoS ONE 2013, 8 (4), e60989. 
(47)  Raschke, W. C.; Baird, S.; Ralph, P.; Nakoinz, I. Functional Macrophage Cell Lines 
Transformed by Abelson Leukemia Virus. Cell 1978, 15 (1), 261–267. 
(48)  Leroux, J.-C.; De Jaeghere, F.; Anner, B.; Doelker, E.; Gurny, R. An Investigation on the 
Role of Plasma and Serum Opsonins on the Evternalization of Biodegradable poly(D,L-
Lactic Acid) Nanoparticles by Human Monocytes. Life Sci. 1995, 57 (7), 695–703. 
(49)  Rytel, M. W.; Stollerman, G. H. The Opsonic Effect of Complement on the Phagocytosis 
of Γ-Globulin-Coated Bentonite Particles. J. Immunol. 1963, 90 (4), 607–611. 
(50)  Deng, Z. J.; Liang, M.; Monteiro, M.; Toth, I.; Minchin, R. F. Nanoparticle-Induced 
Unfolding of Fibrinogen Promotes Mac-1 Receptor Activation and Inflammation. Nat. 
Nanotechnol. 2011, 6 (1), 39–44. 
46 
 
 
(51)  Walkey, C. D.; Olsen, J. B.; Song, F.; Liu, R.; Guo, H.; Olsen, D. W. H.; Cohen, Y.; Emili, 
A.; Chan, W. C. W. Protein Corona Fingerprinting Predicts the Cellular Interaction of Gold 
and Silver Nanoparticles. ACS Nano 2014, 8 (3), 2439–2455. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
 
2.7 Figures and Tables 
 
Figure. 2.1. The amounts of γ-globulins (A) and HSA (B) that bound to the UC-NPs, with and 
without conjugation reaction, and γ-globulins left on GG-NPs after incubation with SDS buffer 
(C) were measured using BCA assay. The graphs represent that pre-coating proteins were 
chemically conjugated to the NPs beside physical adsorption.  
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Table 2.1. Size (hydrodynamic diameter, d), size distribution (polydispersity index, PDI) and 
zeta-potential data for uncoated (control) and protein pre-coated NPs in PBS, and NP diameter 
(d) measured with SEM. 
Type of NPs ζ-potential (mV) d, DLS (nm) PDI d, SEM (nm) 
UC-NPs -29.83 ± 3.00 94.5 ± 1.1 0.086 93.1 ± 14.1 
HSA-NPs -17.03 ± 1.54 343.9 ± 10.0 0.338 98.0 ± 10.5 
GG-NPs -12.79 ± 2.08 749.2 ± 19.6 0.336 101.9 ± 12.8 
corona-UC-NPs -10.18 ± 1.02 157.9 ± 3.0  0.282 102.3 ± 13.3 
corona-HSA-NPs -8.00 ± 3.22 212.8 ± 1.9 0.223 101.3 ± 12.7 
corona-GG-NPs -7.19 ± 3.17 292.6 ± 11.6 0.353 101.8 ± 11.5 
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Figure. 2.2. SEM images and corresponding size distribution plots for each type of NP. (A) SEM 
images and the (B) corresponding size distribution plots of uncoated and pre-coated NPs. (C) 
SEM images and the corresponding (D) size distribution plots of corona-coated NPs. Scale bars 
are 500 nm. 
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Figure. 2.3. SDS-PAGE gels for protein pre-coated NPs (A) and NPs exposed to human 
plasma (B). The black stars designate the bands produced by the proteins used to pre-coat the 
NPs. The red stars indicate the plasma protein bands whose intensities vary between samples. 
These bands are often more intense on GG-NPs than on UC-NPs or HSA-NPs.  
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Table 2.2. Ten most abundant proteins identified by LC-MS/MS. 
corona-UC-NPs corona-HSA-NPs corona-GG-NPs 
Apolipoprotein E Apolipoprotein E Apolipoprotein B100 
Apolipoprotein E chain A Apolipoprotein E4 chain A Apolipoprotein E 
Alpha fibrinogen Kininogen-1 Ig gamma-1 heavy chain 
Apolipoprotein C3 chain A Serum albumin Ig heavy chain 
Fibrinogen chain A Apolipoprotein B100 Ig M chain C 
Apolipoprotein B100 Gelsolin Histidine-rich glycoprotein 
Gelsolin Histidine-rich glycoprotein Complement C3 
Tetranectin Apolipoprotein C3 chain A Complement C4-A 
Kininogen-1 Apolipoprotein J Proapolipoprotein 
Serum albumin Plasminogen Fibrinogen alpha chain 
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Table 2.3. List of all proteins identified by LC-MS/MS in the corona of control NPs (UC-NPs) 
incubated with 55% human plasma. The 10 most abundant proteins in the corona are italicized 
and underlined. 
Accession Wt % Description 
gi|178853 33.18 apolipoprotein E [Homo sapiens] 
gi|157831790 12.28 
Chain A, Structural Basis For Altered Function In The Common 
Mutants Of Human Apolipoprotein-E 
gi|182424 8.30 alpha-fibrinogen precursor [Homo sapiens] 
gi|237823914 5.20 Chain A, Crystal Structure Of Human Fibrinogen 
gi|4504165 2.33 gelsolin isoform a precursor [Homo sapiens] 
gi|186972736 5.30 Chain A, Structure And Dynamics Of Human Apolipoprotein C-Iii 
gi|306569733 3.10 mutant Apo B 100 [Homo sapiens] 
gi|156627579 1.62 tetranectin precursor [Homo sapiens] 
gi|189065306 1.62 unnamed protein product [Homo sapiens] 
gi|642908 0.94 procollagen C-proteinase enhancer protein [Homo sapiens] 
gi|179665 0.83 complement component C3 [Homo sapiens] 
gi|1572721 1.15 megakaryocyte stimulating factor [Homo sapiens] 
gi|4504893 1.33 kininogen-1 isoform 2 precursor [Homo sapiens] 
gi|125184 0.90 Plasma kallikrein (Fletcher factor, Kininogenin) [Homo sapiens] 
gi|33989 0.90 inter-alpha-trypsin inhibitor heavy chain ITIH1 [Homo sapiens] 
gi|33985 0.54 trypsin inhibitor [Homo sapiens] 
gi|4504383 0.89 hepatocyte growth factor activator preproprotein [Homo sapiens] 
gi|178775 1.03 proapolipoprotein, partial [Homo sapiens] 
gi|182439 0.59 fibrinogen gamma chain [Homo sapiens] 
gi|28592 1.23 serum albumin [Homo sapiens] 
gi|1483187 0.59 
inter-alpha-trypsin inhibitor family heavy chain-related protein (IHRP) 
[Homo sapiens] 
gi|182430 0.59 beta-fibrinogen precursor, partial [Homo sapiens] 
gi|4503011 0.93 carboxypeptidase N catalytic chain precursor [Homo sapiens] 
gi|387031 0.91 plasminogen, partial [Homo sapiens] 
gi|1082300 0.58 collagen alpha 1(XVIII) chain - human (fragment) 
gi|183116 1.00 insulin-like growth factor-binding protein [Homo sapiens] 
gi|17426607 0.86 coagulation factor V jinjiang B domain [Homo sapiens] 
gi|14277770 0.87 
Chain A, Nmr Structure Of Human Apolipoprotein C-Ii In The Presence 
Of Sds 
gi|180352 0.58 coagulation factor XI [Homo sapiens] 
gi|36573 0.93 unnamed protein product [Homo sapiens] 
gi|10834982 0.64 insulin-like growth factor-binding protein 5 precursor [Homo sapiens] 
gi|178855 0.59 apolipoprotein J precursor [Homo sapiens] 
gi|4506427 0.31 retinoic acid receptor responder protein 2 precursor [Homo sapiens] 
gi|183910 0.58 heparin cofactor II precursor [Homo sapiens] 
gi|34783164 0.30 Selenoprotein P, plasma, 1 [Homo sapiens] 
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Table 2.3 (Cont.)  
gi|112910 0.30 
Alpha-2-HS-glycoprotein (Alpha-2-Z-globulin, Ba-alpha-2-glycoprotein, 
Fetuin-A)  [Homo sapiens] 
gi|4504489 0.60 histidine-rich glycoprotein precursor [Homo sapiens] 
gi|291922 0.27 complement factor B [Homo sapiens] 
gi|31397 0.32 fibronectin precursor [Homo sapiens] 
gi|179674 0.61 complement component C4A [Homo sapiens] 
gi|2104968 0.28 chondroadherin [Homo sapiens] 
gi|179726 0.28 C9 complement protein, partial [Homo sapiens] 
gi|229479 0.29 lipoprotein Gln I 
gi|6103597 0.32 apolipoprotein(a) [Homo sapiens] 
gi|619383 0.30 apolipoprotein D, apoD [human, plasma, Peptide, 246 aa] 
gi|573114 0.30 C1q B-chain precursor [Homo sapiens] 
gi|178757 0.29 apolipoprotein A-IV precursor [Homo sapiens] 
gi|4758502 0.28 hyaluronan-binding protein 2 isoform 1 preproprotein [Homo sapiens] 
gi|259352 0.31 serum amyloid A [Homo sapiens] 
gi|553734 0.57 putative [Homo sapiens] 
gi|27734883 0.28 probable E3 ubiquitin-protein ligase TRIML2 [Homo sapiens] 
gi|12232634 0.29 apolipoprotein L-I [Homo sapiens] 
gi|180550 0.29 plasma serine protease inhibitor precursor [Homo sapiens] 
gi|28549 0.32 alpha globin [Homo sapiens] 
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Table 2.4. List of all proteins identified by LC-MS/MS in the corona of HSA pre-coated NPs 
(HSA-NPs) incubated with 55% human plasma. The 10 most abundant proteins in the corona 
are italicized and underlined. 
Accession Wt % Description 
gi|178853 45.31 apolipoprotein E [Homo sapiens] 
gi|15826311 8.86 Chain A, Apolipoprotein E4 (Apoe4), 22k Fragment 
gi|4504893 8.02 kininogen-1 isoform 2 precursor [Homo sapiens] 
gi|4504489 3.38 histidine-rich glycoprotein precursor [Homo sapiens] 
gi|28592 4.46 serum albumin [Homo sapiens] 
gi|186972736 2.34 Chain A, Structure And Dynamics Of Human Apolipoprotein C-Iii 
gi|4504165 3.63 gelsolin isoform a precursor [Homo sapiens] 
gi|28780 3.92 apo-B100 precursor [Homo sapiens] 
gi|36575 2.26 unnamed protein product [Homo sapiens] 
gi|178855 2.31 apolipoprotein J precursor [Homo sapiens] 
gi|78101267 0.78 Chain A, Human Complement Component C3 
gi|119567981 1.22 lipoprotein, Lp(a) [Homo sapiens] 
gi|4503011 1.24 carboxypeptidase N catalytic chain precursor [Homo sapiens] 
gi|178775 0.86 proapolipoprotein, partial [Homo sapiens] 
gi|190026 1.61 plasminogen [Homo sapiens] 
gi|237823914 0.77 Chain A, Crystal Structure Of Human Fibrinogen 
gi|182430 0.79 beta-fibrinogen precursor, partial [Homo sapiens] 
gi|33985 0.81 trypsin inhibitor [Homo sapiens] 
gi|38492828 0.98 Chain C, Globular Head Of The Complement System Protein C1q 
gi|180352 1.25 coagulation factor XI [Homo sapiens] 
gi|4758502 0.80 hyaluronan-binding protein 2 isoform 1 preproprotein [Homo sapiens] 
gi|261691 0.98 
insulin-like growth factor binding protein 30 kda form, 30 kda IGFBP 
{N-terminal} [human, cerebrospinal fluid, Peptide Partial, 18 aa] 
gi|183910 0.39 heparin cofactor II precursor [Homo sapiens] 
gi|31965 0.35 factor H [Homo sapiens] 
gi|573114 0.41 C1q B-chain precursor [Homo sapiens] 
gi|259352 0.41 serum amyloid A [Homo sapiens] 
gi|553734 0.76 putative [Homo sapiens] 
gi|178277 0.40 S-adenosylhomocysteine hydrolase [Homo sapiens] 
gi|125184 0.36 Plasma kallikrein (Fletcher factor, Kininogenin) [Homo sapiens] 
gi|7022844 0.36 unnamed protein product [Homo sapiens] 
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Table 2.5. List of all proteins identified by LC-MS/MS in the corona of γ-globulins pre-coated 
NPs (GG-NPs) incubated with 55% human plasma. The 10 most abundant proteins in the 
corona are italicized and underlined. 
Accession Wt % Description 
gi|178804 6.97 apolipoprotein B-100 precursor [Homo sapiens] 
gi|115298678 2.72 complement C3 precursor [Homo sapiens] 
gi|4504489 2.74 histidine-rich glycoprotein precursor [Homo sapiens] 
gi|178849 3.46 apolipoprotein E [Homo sapiens] 
gi|7767178 1.36 Chain A, Apolipoprotein E3 (Apoe3) Truncation Mutant 165 
gi|47077384 2.05 unnamed protein product [Homo sapiens] 
gi|10334587 2.69 immunoglobulin heavy chain [Homo sapiens] 
gi|578468798 2.91 immunoglobulin heavy chain, partial [Homo sapiens] 
gi|34528531 2.44 unnamed protein product [Homo sapiens] 
gi|166007160 2.78 Chain C, Solution Structure Of Human Immunoglobulin M 
gi|170684606 1.26 immunoglobulin kappa 1 light chain [Homo sapiens] 
gi|19717684 2.92 
immunoglobulin gamma-1 heavy chain constant region [Homo 
sapiens] 
gi|229526 1.73 protein Rei,Bence-Jones 
gi|34527453 1.33 unnamed protein product [Homo sapiens] 
gi|170684494 0.60 immunoglobulin kappa 1 light chain [Homo sapiens] 
gi|229585 1.25 Ig A1 Bur 
gi|125761 0.61 RecName: Full=Ig kappa chain V-I region DEE 
gi|2414492 1.21 immunoglobulin heavy chain, constant region [Homo sapiens] 
gi|119602344 1.01 hCG2038942 [Homo sapiens] 
gi|34527290 0.72 unnamed protein product [Homo sapiens] 
gi|4176416 0.52 IgG heavy chain [Homo sapiens] 
gi|3659942 0.52 
Chain L, Crystal Structure Of A Human Igm Rheumatoid Factor Fab In 
Complex With Its Autoantigen Igg Fc 
gi|270047622 0.50 
Chain H, Crystal Structure Of Anti-Hiv-1 Fab 447-52d In Complex With 
V3 Peptide W2rw020 
gi|15825659 0.52 
Chain A, Human Factor Viii C2 Domain Complexed To Human 
Monoclonal Bo2c11 Fab 
gi|106586 0.85 Ig kappa chain V-III (KAU cold agglutinin) - human 
gi|241913101 0.85 Chain L, Crystal Structure Of Human Igg Abt-325 Fab Fragment 
gi|896272 0.58 
This CDS feature is included to show the translation of the 
corresponding V_region. Presently translation qualifiers on V_region 
features are illegal, partial [Homo sapiens] 
gi|323433100 0.56 immunoglobulin variable region [Homo sapiens] 
gi|223229 0.52 protein NIG51 lambda,Bence-Jones 
gi|519674670 0.58 immunoglobulin A heavy chain variable region, partial [Homo sapiens] 
gi|229536 0.51 Ig A L 
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Table 2.5 (Cont.) 
gi|323463159 0.51 
Chain L, Crystal Structure Of Fab Del2d1, A Deletion Variant Of Anti- 
Influenza Antibody 2d1 
gi|114147642 0.60 immunoglobulin heavy chain variable region [Homo sapiens] 
gi|51103469 0.58 immunoglobulin variable region VH gamma domain [Homo sapiens] 
gi|125795 1.12 Ig kappa chain V-III region B6 
gi|10636875 0.60 immunoglobulin heavy chain variable region [Homo sapiens] 
gi|28559046 0.55 Ig rearranged H-chain V-region [Homo sapiens] 
gi|197115867 0.60 immunoglobulin heavy chain variable region [Homo sapiens] 
gi|11275306 0.85 anti TNF-alpha antibody light-chain Fab fragment [Homo sapiens] 
gi|323432812 0.98 immunoglobulin variable region [Homo sapiens] 
gi|12750761 0.52 immunoglobulin heavy chain variable region [Homo sapiens] 
gi|37777869 0.56 immunoglobulin heavy chain variable region [Homo sapiens] 
gi|58222279 0.59 
anti-tetanus toxoid immunoglobulin heavy chain variable region [Homo 
sapiens] 
gi|486865 0.59 Ig heavy chain V region (clone alpha-TNF-A1) - human  (fragment) 
gi|13774112 0.52 anti TNF-alpha antibody heavy-chain Fab fragment [Homo sapiens] 
gi|16075550 1.38 immunoglobulin kappa chain variable region [Homo sapiens] 
gi|491668735 0.51 
Chain H, Crystal Structure Of Human Fab Pgt122, A Broadly Reactive 
And Potent Hiv-1 Neutralizing Antibody 
gi|304562830 0.58 immunoglobulin gamma 1 heavy chain variable region [Homo sapiens] 
gi|225698080 0.51 Chain H, Igg1 Fab Characterized By HD EXCHANGE 
gi|340780637 0.51 
Chain H, Crystal Structure Of Broadly Neutralizing Antibody Cr8020 
Bound To The Influenza A H3 Hemagglutinin 
gi|323432927 0.57 immunoglobulin variable region [Homo sapiens] 
gi|440576089 0.31 alternative protein ZNF251 [Homo sapiens] 
gi|4503689 1.81 fibrinogen alpha chain isoform alpha-E preproprotein [Homo sapiens] 
gi|356582273 2.16 complement C4-A isoform 2 preproprotein [Homo sapiens] 
gi|4504165 0.69 gelsolin isoform a precursor [Homo sapiens] 
gi|119598586 1.55 kininogen 1, isoform CRA_b [Homo sapiens] 
gi|178775 2.06 proapolipoprotein, partial [Homo sapiens] 
gi|182439 1.04 fibrinogen gamma chain [Homo sapiens] 
gi|114062 1.00 Apolipoprotein(a) 
gi|4504383 0.21 hepatocyte growth factor activator preproprotein [Homo sapiens] 
gi|186972736 1.36 Chain A, Structure And Dynamics Of Human Apolipoprotein C-Iii 
gi|547198 0.21 
LPS-binding protein, LBP=lipopolysaccharide-binding protein [human, 
liver, Peptide, 481 aa] 
gi|105990535 1.13 coagulation factor V precursor [Homo sapiens] 
gi|178855 0.73 apolipoprotein J precursor [Homo sapiens] 
gi|28592 1.56 serum albumin [Homo sapiens] 
gi|4503011 0.73 carboxypeptidase N catalytic chain precursor [Homo sapiens] 
gi|642908 0.48 procollagen C-proteinase enhancer protein [Homo sapiens] 
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gi|14277770 0.26 
Chain A, Nmr Structure Of Human Apolipoprotein C-Ii In The Presence 
Of Sds 
gi|181402 0.73 epidermal cytokeratin 2 [Homo sapiens] 
gi|125184 0.71 Plasma kallikrein (Fletcher factor, Kininogenin) [Homo sapiens] 
gi|33989 0.71 inter-alpha-trypsin inhibitor heavy chain ITIH1 [Homo sapiens] 
gi|182430 0.47 beta-fibrinogen precursor, partial [Homo sapiens] 
gi|381353319 0.71 
Chain A, The X-ray Crystal Structure Of Full-length Type Ii Human 
Plasminogen 
gi|156627579 0.24 tetranectin precursor [Homo sapiens] 
gi|34783164 0.48 Selenoprotein P, plasma, 1 [Homo sapiens] 
gi|180550 0.48 plasma serine protease inhibitor precursor [Homo sapiens] 
gi|37409 0.24 Tetranectin [Homo sapiens] 
gi|3127926 0.17 collagen type VI, alpha 3 chain [Homo sapiens] 
gi|190192 0.22 serum paraoxonase [Homo sapiens] 
gi|13325075 0.45 sulfhydryl oxidase 1 isoform a precursor [Homo sapiens] 
gi|36573 0.46 unnamed protein product [Homo sapiens] 
gi|47846617 0.25 immunoglobulin heavy chain variable region [Homo sapiens] 
gi|28317 0.48 unnamed protein product [Homo sapiens] 
gi|125805 0.25 Ig kappa chain V-III region POM 
gi|179692 0.71 complement component C5, partial [Homo sapiens] 
gi|179950 0.23 catalase, partial [Homo sapiens] 
gi|33985 0.43 trypsin inhibitor [Homo sapiens] 
gi|12232634 0.23 apolipoprotein L-I [Homo sapiens] 
gi|1483187 0.67 
inter-alpha-trypsin inhibitor family heavy chain-related protein (IHRP) 
[Homo sapiens] 
gi|899271 0.23 complement C7 [Homo sapiens] 
gi|180352 0.70 coagulation factor XI [Homo sapiens] 
gi|59709551 0.25 immunoglobulin heavy chain variable region [Homo sapiens] 
gi|33319288 0.25 Ig heavy chain variable region, VH3 family [Homo sapiens] 
gi|261691 0.58 
insulin-like growth factor binding protein 30 kda form, 30 kda IGFBP 
{N-terminal} [human, cerebrospinal fluid, Peptide Partial, 18 aa] 
gi|304562846 0.25 immunoglobulin gamma 1 heavy chain variable region [Homo sapiens] 
gi|70888092 0.25 immunoglobulin lambda light chain variable region [Homo sapiens] 
gi|178757 0.23 apolipoprotein A-IV precursor [Homo sapiens] 
gi|183116 0.22 insulin-like growth factor-binding protein [Homo sapiens] 
gi|180249 0.24 ceruloplasmin, partial [Homo sapiens] 
gi|3540261 0.24 IgG heavy chain variable region, partial [Homo sapiens] 
gi|2982023 0.24 
Chain H, Igg-Fab Fragment Of Engineered Human Monoclonal 
Antibody Ctm01 
gi|5102661 0.25 immunoglobulin heavy chain variable region [Homo sapiens] 
gi|435985 0.25 immunoglobulin heavy chain, partial [Homo sapiens] 
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gi|4502495 0.23 complement C1s subcomponent precursor [Homo sapiens] 
gi|901864 0.23 complement 8 alpha subunit [Homo sapiens] 
gi|4758502 0.22 hyaluronan-binding protein 2 isoform 1 preproprotein [Homo sapiens] 
gi|13160401 0.25 immunoglobulin G heavy chain variable region [Homo sapiens] 
gi|2345018 0.24 Ig heavy chain VH3 region [Homo sapiens] 
gi|93007610 0.25 
anti-Rh(D) antibody immunoglobulin heavy chain variable region 
[Homo sapiens] 
gi|23200172 0.47 Chain A, Crystal Structure Of Native Heparin Cofactor Ii 
gi|349587578 0.58 
Chain B, Structure Of N-Terminal Domain Of Candida Albicans Als9-2 
In Complex With Human Fibrinogen Gamma Peptide 
gi|337758 0.23 pre-serum amyloid P component [Homo sapiens] 
gi|4456550 0.25 immunoglobulin heavy chain variable region [Homo sapiens] 
gi|157058679 0.25 immunoglobulin heavy chain variable region [Homo sapiens] 
gi|435476 0.22 cytokeratin 9 [Homo sapiens] 
gi|307228 0.21 completement component C6 [Homo sapiens] 
gi|996102 0.24 
Chain H, A Conformation Of Cyclosporin A In Aqueous Environment 
Revealed By The X-Ray Structure Of A Cyclosporin-Fab Complex 
gi|3892018 0.25 Chain B, Ribonuclease Inhibitor-Angiogenin Complex 
gi|16075862 0.25 immunoglobulin heavy chain variable region [Homo sapiens] 
gi|29575 0.22 
complement C8-beta propetide /map='1p36.2- p22.1' 
/hgml_locus_uid='LE0166P' [Homo sapiens] 
gi|1082300 0.21 collagen alpha 1(XVIII) chain - human (fragment) 
gi|578820597 0.21 PREDICTED: PHD finger protein 21A isoform X12 [Homo sapiens] 
gi|291922 0.21 complement factor B [Homo sapiens] 
gi|693933 0.24 2-phosphopyruvate-hydratase alpha-enolase [Homo sapiens] 
gi|346196 0.25 Ig lambda chain V region - human 
gi|118425772 0.25 immunoglobulin light chain variable region [Homo sapiens] 
gi|809369 0.27 Chain A, Crystal Structure Of Recombinant Human Platelet Factor 4 
gi|28810 0.23 Beta-2-glycoprotein I apolipoprotein H [Homo sapiens] 
gi|39937971 0.24 immunoglobulin heavy chain variable region [Homo sapiens] 
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Figure. 2.4. The normalized abundances of identified proteins in the protein corona, grouped 
according to molecular weight (A) and plasma protein classification (B). The LC-MS/MS analysis 
shows that the protein pre-coatings altered the composition of the protein corona. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
 
Table 2.6. Size (hydrodynamic diameter, d) and size distribution (polydispersity index, PDI) for 
GG-NPs, corona-GG-NPs, and corona-UC-NPs in serum-free medium. 
Type of NPs d, hydrodynamic (nm) PDI 
GG-NPs 755.3 ± 13.3 0.279 
corona-GG-NPs 374.1 ± 3.5  0.349 
corona-UC-NPs 280.6 ± 3.4 0.340 
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Figure. 2.5. Confocal microscope images of RAW 264.7 cells incubated with corona-UC-NPs 
(A), corona-GG-NPs (B), and GG-NPs that were not exposed to plasma (C). These results show 
that the uptake of the GG-NPs was higher than that of the corona-UC-NPs or corona-GG-NPs. 
Scale bars are 20 μm.  
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Figure. 2.6. Flow cytometry results for NPs’ uptake in serum free (A), and 10% serum medium 
(B). The results were quantified and shown in bar graph (C). GG-NPs had significantly higher 
uptake than corona-UC-NPs and corona-GG-NPs. 
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Figure. 2.7. Flow cytometry results for NPs’ uptake incubated with cells for 6 h in serum free 
medium. GG-NPs showed higher cellular uptake than corona-UC-NPs and corona-GG-NPs. 
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Figure. 2.8. Immuno-dot blot assays of the amount of immunoglobulins exposed on the 
surfaces of NPs. (A) Higher amounts of immunoglobulins were detected on the GG-NPs (3) 
than on corona-UC-NPs (1), corona-GG-NPs (2), or GG-NPs exposed to medium consisting of 
DMEM/serum (9/1 vol/vol) (4). (B) The amount of immunoglobulins detected on the GG-NPs 
decreased slightly when the dot blot was performed with a blocking solution containing 10% 
serum instead of the standard blocking solution (1% skim milk in PBS). 
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Fig. 2.9. Confocal microscopy images of RAW 264.7 cells that were incubated with GG-NPs, 
corona-GG-NPs, and corona-UC-NPs (red) for 2 h, and labeled with anti-CD64 (green) and 
Hoechst 33342 (blue). Colocalization of NPs with CD64 receptor was the highest for the GG-
NPs. Scale bars are 20 μm.  
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CHAPTER 3 
THE IMPORTANCE OF SELECTING A PROPER BIOLOGICAL MILIEU FOR PROTEIN 
CORONA ANALYSIS IN VITRO: HUMAN PLASMA VERSUS HUMAN SERUM 
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3.1 Introduction 
Nanoparticles (NPs) are promising therapeutic delivery vehicles which can be loaded with 
pharmaceuticals and/or imaging agents2,3 and functionalized with targeting moieties4,5 that may 
enable selectively delivering their payloads to the desired location in the body.6–8 As soon as 
NPs are injected into the body, proteins and other biomolecules, such as lipids, bind to their 
surfaces and form a layer that is called the “protein corona”.9–14 This protein corona can 
compromise cellular uptake and targeting efficiency by covering the targeting ligands.5,15–17 
Protein corona formation also affects the NPs’ distributions inside the body18–21 and within 
individual cells.22 Thus, knowledge of blood protein adsorption onto NPs and its effects on 
biological phenomena are critical for the development of safer and more efficient NP-based drug 
delivery systems. 
An approach that is widely used to simplify studies of protein–NP interactions in the body 
and the effects of protein corona formation on various biological phenomena is to expose NPs 
to biological fluids (e.g., human serum, human plasma, and fetal bovine serum) in vitro. Then 
the effects of protein adsorption on the NPs’ interactions with cultured cells such as uptake or in 
vitro targeting efficiency are characterized.15,22–24 Although the exposure of NPs to blood 
proteins in vivo may be more comprehensive,25,26 such in vitro studies are convenient platforms 
for preliminary studies of protein corona formation. While human plasma was used as the 
protein-containing medium for corona formation in many in vitro studies,11,12,27–30 numerous 
other studies used human or bovine serum to prepare NP–protein complexes.23,31–39 While both 
plasma and serum are obtained from blood, their compositions are very different due to 
dissimilar preparation procedures. The preparation of plasma from blood involves the addition of 
anticoagulant reagents, followed by centrifugation to remove the blood cells. In contrast, serum 
preparation involves first coagulating the blood, followed by centrifugation to remove the blood 
cells and coagulated material. This process depletes the serum of coagulation factors, such as 
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fibrinogen, and lowers its protein concentration.40 This difference could significantly affect 
protein corona composition, and hence, the effects of this protein coating on the NPs’ physical 
and biological characteristics. Therefore, identical NPs that have two different corona 
compositions, one obtained from NP incubation with human serum and the other with human 
plasma, may elicit very different cellular responses. Thus, the biological fluid that is used for 
protein corona formation must be carefully selected to ensure that the biological phenomena 
observed is representative of that occurring in the body.  
Here, we explore the differences in the protein coronas that are obtained when NPs are 
incubated with human plasma and human serum. Silica NPs were exposed to either human 
plasma or human serum to form the protein corona. These NP-protein complexes were 
characterized regarding their size, surface charge, and the amount of proteins bound to their 
surfaces. Gel electrophoresis and liquid chromatography–mass spectrometry/mass 
spectrometry (LC–MS/MS) were used to compare the compositions of their protein coronas in 
terms of protein size and identity. Finally, the effects of the two different corona compositions on 
NP uptake was studied via incubation of serum exposed and plasma exposed NPs with 
macrophage (RAW 264.7) and fibroblast (NIH3T3) cells. 
3.2 Materials and Methods 
3.2.1 Materials 
Ammonium hydroxide (28.0–30.0% as NH3) and carboxyethyl-silanetriol sodium salt (25% 
in water) were purchased from Macron Fine Chemicals and Gelest Inc., respectively. Phosphate 
buffered saline (PBS) was purchased from Lonza. The bicinchoninic acid (BCA) protein assay 
kit was purchased from Pierce Biotechnology, Inc. MSG-Trypsin was purchased from G-
Biosciences. 2X Laemmli sample buffer, QC Colloidal Coomassie Stain, and 4–20% 
polyacrylamide Mini PROTEAN Precast Gels were purchased from Bio-Rad. RAW 264.7 cells 
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were kindly provided by Prof. Ed Roy (University of Illinois at Urbana-Champaign, USA). NIH 
3T3 cells were purchased from ATCC. All other chemicals were purchased from Sigma-Aldrich. 
3.2.2 Synthesis of silica NPs 
A well-mixed solution of 1 mL methanol, 360 μL deionized (DI) water, and 80 μL 
ammonium hydroxide was prepared, 62.5 μL tetraethyl orthosilicate (TEOS) was added, and the 
solution was stirred at rt for 2 h. The resulting NPs were collected by centrifuging the solution, 
and washed with ethanol and DI water. The NPs were functionalized with carboxylic acid 
moieties by adding 20 μL carboxyethyl-silanetriol sodium salt (25% in water) to silica NPs (10 
mg) suspended in 1 mL PBS.41 After stirring the solution for 4 h, the carboxylic acid-
functionalized NPs were collected by centrifugation, washed with PBS, and dispersed in DI 
water. Fluorescent silica NPs were synthesized following a previously reported procedure16,42 
with minor modification. Briefly, RITC-silane conjugate was added to a solution of silica NPs that 
were prepared as described above. After stirring for 12 h, 20 μL of carboxyethyl-silanetriol 
sodium salt (25% in water) was added to the solution, and the mixture was stirred for another 12 
h. The resulting fluorescent silica NPs were collected by centrifugation, washed with ethanol 
and DI water, and dispersed in DI water. 
3.2.3 Formation of NPs with hard coronas  
NPs (500 μg) were incubated with human plasma or human serum solutions that mimic the 
protein concentration in vivo (55% human plasma or human serum in PBS) for 1 h at 37 °C. The 
NP–protein complexes were collected via centrifugation, washed twice with cold (4 °C) PBS, 
and dispersed in PBS. 
3.2.4 Characterization on NPs’ physical properties 
For hydrodynamic diameter and surface charge characterization, fluorescent NPs were 
dispersed in PBS (0.2 mg/mL), and measurements were performed using a Brookhaven 
ZetaPALS instrument. The hydrodynamic diameters of the pristine NPs were measured in 
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deionized water instead of PBS due to their aggregation in PBS. To characterize NP size 
distribution by scanning electron microscopy (SEM), NPs were coated with Au/Pd using an 
Emitech K575 sputter coater, and imaged with a Hitachi S-4800 high resolution scanning 
electron microscope. For each type of NP, the diameters of 50 NPs were measured using 
Image J software. 
3.2.5 Quantitative analysis of proteins bound to the NPs 
The amounts of proteins in the hard corona-coated fluorescent NPs were measured using a 
BCA protein assay, which was performed following the manufacturer’s instructions. 
3.2.6 Analysis of proteins in the hard-corona by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) 
200 μg of each hard corona-coated non-fluorescent NPs (10 μg/μL, 20 μL) were incubated 
in 2X Laemmli sample buffer without reducing agent at 85 °C for 5 min, then cooled to rt and 
subjected to SDS-PAGE separation on 4–20% polyacrylamide Mini PROTEAN precast gels. 
After SDS-PAGE, the gel was fixed in acetic acid:methanol:water = 1:4:5 (v:v:v), stained with 
QC Colloidal Coomassie Stain overnight at rt, and then destained in water for 2–3 h. 
ImageQuant LAS4010 Imager (GE Healthcare) was used for imaging stained gels. 
3.2.7 Identifying the proteins bound to the NPs by liquid chromatography–mass 
spectrometry/mass spectrometry (LC–MS/MS) 
After collecting hard corona-coated non-fluorescent NPs by centrifugation (10,000 g for 30 
min), the proteins in their coronas were digested with MSG-Trypsin at a ratio of 1:10–1:50 for 15 
min with a CEM Discover Microwave Digestor (Mathews, SC) at 55 °C and a maximum power of 
60 W. Next, the digested peptides were separated from the NPs, lyophilized, and suspended in 
5% acetonitrile with 0.1% formic acid. A Thermo Dionex Ultimate RSLC3000 operating in nano 
mode at 300 μL/min with a gradient from 99.9% water with 0.1% formic acid to 99.9% 
acetonitrile with 0.1% formic acid over 120 min was used to perform LC–MS/MS on the protein 
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digests. A Thermo Acclaim PepMap 100 (100 μm × 2 cm) trap column and a Thermo Acclaim 
PepMap RSLC (75 μm × 15 cm) analytical column were employed. Mascot Distiller was used to 
convert the Xcalibur raw files into peak lists that were submitted to an in-house Mascot Server 
and searched against specific NCBI-NR protein databases. For each sample, the weight 
percent (wt%) of each protein in the hard-corona was calculated based on its molecular weight 
(Mi) and exponentially modified protein abundance index (emPAIi) using the following 
equation43: 
Protein Content (wt %) =
emPAIi × 𝑀𝑖
∑(emPAIi × 𝑀𝑖)
× 100 
3.2.8 Cell culture 
RAW 264.7 cells and NIH 3T3 cells were cultured in DMEM (Dulbecco’s Modified Eagle’s 
Medium) supplemented with 1% penicillin/streptomycin and 10% fetal bovine serum (FBS) or 
10% newborn calf serum, respectively, in a 5% CO2 incubator at 37 °C. 
3.2.9 Analysis of NP cellular uptake by flow cytometry 
RAW 264.7 cells and NIH 3T3 cells at 50–70% confluence in 60 mm cell culture dishes 
were incubated with fluorescent nanoparticles at final concentration of 20 μg/mL in OptiMEM for 
2 h at 37 °C in a 5% CO2 incubator. After NP incubation and washing with OptiMEM, RAW 
264.7 cells were scrapped off the dish with a cell lifter in OptiMEM, transferred to a 15 mL 
conical tube, and resuspended in OptiMEM (2 million cells/mL) for flow cytometry. NIH 3T3 cells 
were detached from the dish with 0.25% trypsin/EDTA, washed with cell culture media 
containing 10% calf serum to neutralize the trypsin activity, centrifuged, and finally resuspended 
in OptiMEM (2 million cells/mL) for flow cytometry. Flow cytometry was performed with a BD 
LSR II Flow Cytometry Analyzer using a blue laser and 575/26 bandpass filter. 
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3.2.10 Analysis of NP cellular uptake by confocal fluorescence microscopy 
Cells were plated in glass-bottomed dishes (In Vitro Scientific), cultured until they reached 
to 50–70% confluence, and incubated with 20 μg/mL of fluorescent NPs in OptiMEM for 2 h at 
37 °C in a 5% CO2 incubator. After thorough washing, the cells were fixed with 4% 
paraformaldehyde for 15–20 min at rt, washed with PBS, and imaged in PBS with a LSM700 
laser scanning confocal microscope (Carl Zeiss). The NPs were visualized using 555 nm laser 
excitation. 
3.3 Results 
3.3.1 Characterization of protein corona-coated NPs 
We compared the total protein contents, surface charges and sizes of silica NPs that were 
exposed to human serum or human plasma solutions that mimic the protein concentration in the 
blood stream (55% human serum or human plasma in PBS; Table 3.1). Measurement of the 
total protein content on the resulting serum-exposed NPs (SE-NPs) and plasma-exposed NPs 
(PE-NPs) with a BCA assay indicated that more protein was bound to the PE-NPs than to the 
SE-NPs. SEM images of pristine NPs (NPs without protein coronas), SE-NPs, and PE-NPs 
revealed exposure to human serum and human plasma solutions increased the NPs’ mean 
diameters by approximately 11 and 16 nm, respectively (Fig. 3.1). Dynamic light scattering 
(DLS) measurements confirmed that NP exposure to human serum and plasma solutions 
increased the NPs’ diameters, as well as their polydispersity index (PDI; Table 3.1). The 
diameters measured with DLS were somewhat larger than those measured with SEM, which 
may be due to the higher sensitivity of DLS to small numbers of NP aggregates.44 Nonetheless, 
both techniques indicated that the PE-NPs had larger diameters than the SE-NPs, which is 
consistent with the detection of more proteins on the PE-NPs than the SE-NPs. Zeta potential 
measurements indicated that SE-NPs and PE-NPs had similar surface charges. 
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3.3.2 Comparison of protein corona composition for SE-NPs and PE-NPs 
SDS-PAGE was performed to separate and visualize the proteins in the hard coronas that 
formed on NPs exposed to human serum and human plasma solutions that mimicked the 
protein concentrations in the blood stream (Fig. 3.2A). The profiles of the separated proteins on 
the gels reveal differences in the identities and molecular weights of the proteins bound to the 
SE-NPs and PE-NPs. Several protein bands appeared to differ between the SE-NPs and PE-
NPs. Low molecular weight proteins (below 25 kDa) were more abundant in the coronas of the 
SE-NPs than the PE-NPs (Fig. 3.2B). In contrast, a higher fraction of the proteins in the corona 
of the PE-NPs had molecular weights greater than 75 kDa (Fig. 3.2B). These results suggest 
that human serum and human plasma produce hard coronas with dissimilar protein 
compositions. 
Next, we identified the proteins in the hard coronas using LC–MS/MS. The ten most 
abundant proteins detected in the coronas of SE-NPs and PE-NPs are listed in Table 3.2 (see 
Tables 3.3 and 3.4 for full lists of the identified proteins). While various apolipoproteins were 
among the most abundant protein components detected in the coronas of both the PE-NPs and 
SE-NPs, several proteins that function as coagulation proteins were more abundant on the PE-
NPs than the SE-NPs. For example, fibrinogen and kininogen-1 were major components in the 
hard corona of the PE-NPs, but the coronas of the SE-PEs contained no fibrinogen and very 
little kininogen-1. 
We also compared the compositions of protein coronas on the PE-NPs and SE-NPs in 
terms of the proteins’ biological functions (Fig. 3.3). While lipoproteins were the most abundant 
protein class identified in the coronas of both the SE-NPs and PE-NPs, the relative weight 
percentage (wt%) of lipoproteins in the coronas of the SE-NPs (93%) was nearly twice that in 
the coronas of the PE-NPs (58%). Likewise, coagulation proteins (e.g., fibrinogen and 
kininogen-1) were the second most abundant corona protein for both the PE-NPs and SE-NPs, 
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but the relative wt% of coagulation proteins in the PE-NPs (22%) was seven times higher than 
that in the SE-NPs (3%). In addition, the wt% of complement factors (e.g., complement C3 and 
C4A) in the PE-NPs (2.3%) was nearly four times higher than that in the SE-NPs (0.6%). 
Together the SDS-PAGE and LC–MS/MS results demonstrate that the compositions of the 
protein coronas for the SE-NPs and PE-NPs vary significantly in terms of their constituents’ 
molecular weights and functions. 
3.3.3 Uptake of SE-NPs and PE-NPs by macrophage and fibroblast cells 
The differences in the functions of the proteins that form the coronas on the SE-NPs and 
PE-NPs could affect how cells interact with these NPs. Therefore, we assessed the uptake of 
the SE-NPs and PE-NPs by cells. Because opsonins, such as fibrinogen and complement 
factors, were more abundant in the corona of PE-NPs, and they enhance NP uptake by immune 
cells,18 we first assessed NP uptake by macrophage immune cells.  
SE-NPs and PE-NPs were added to RAW 264.7 macrophage cells in serum-free medium. 
Evaluation of NP cellular uptake by flow cytometry indicated that the uptake of the PE-NPs was 
higher than the SE-NPs (Fig. 3.4A). Further evaluation confirmed the difference was statistically 
significant (Fig. 3.4B). Additionally, confocal microscopy imaging confirmed that PE-NP uptake 
by the RAW 264.7 macrophage cells was higher than that of SE-NPs (Fig. 3.5). 
To investigate whether the higher uptake of PE-NPs was specific to immune cells, the 
uptake of the SE-NPs and PE-NPs was also assessed in a non-immune cell line, namely NIH 
3T3 fibroblast cells. SE-NPs and PE-NPs were incubated with NIH 3T3 mouse fibroblast cells 
under the same condition as those used for the macrophages (2 h in serum free medium). Flow 
cytometry analysis showed that in contrast to the macrophages, there was no significant 
difference between the uptake of SE-NPs and PE-NPs by NIH 3T3 cells (Fig. 3.6). This was 
further confirmed by confocal microscopy imaging, where the amounts of SE-NPs and PE-NPs 
internalized by the NIH 3T3 fibroblast cells were similar (Fig. 3.7). Comparison of SE-NP and 
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PE-NP uptake by the fibroblasts and macrophages indicates the NIH3T3 fibroblast cells 
internalized lower amounts of both types of NPs than the RAW 264.7 macrophages. 
3.4 Discussion 
When NPs are injected into the blood stream, the adsorption of blood proteins to the NPs 
leads to the formation of the protein corona. A simple method to predict protein–NP interactions 
before performing more complex in vivo experiments is to expose NPs to biological solutions 
obtained from blood ex vivo and characterize the consequences in vitro. Previous studies have 
shown that the concentration of these biological solutions affects protein corona composition, 
which in turn impacts the NPs’ interactions with biomolecules, their cytotoxicity, and cellular 
uptake.45,46 However, little attention had been paid to whether the identity of the solution used to 
create the protein corona, namely serum versus plasma, affects the NPs’ physical properties 
and cellular uptake. Serum and plasma differ in composition, as coagulation factors are present 
in plasma but depleted from serum. Therefore, the goal of this study was to probe how the use 
of human plasma versus human serum affects corona composition and NP uptake in vitro. 
Characterization of NPs that were exposed to human plasma and human serum indicated 
that more proteins were bound in the PE-NPs, resulting in slightly (∼5 nm) larger particle size. 
This result is consistent with higher concentration of blood proteins in plasma than in serum,40 
though it may alternatively reflect a higher affinity of the coagulation factors that are more 
abundant in plasma than serum for the NPs’ surfaces. Indeed, high levels of the coagulation 
protein, fibrinogen, have been detected on gold NPs exposed to plasma solutions,47 and we 
also detected high amounts of fibrinogen absorbed to the PE-NPs, but not the SE-NPs. In fact, 
our identification of bound proteins by LC–MS/MS analysis indicated coagulation proteins were 
notably more abundant on the PE-NPs than the SE-NPs. This finding is not surprising because 
coagulation factors are present in plasma, but are depleted from serum. Furthermore, the PE-
NPs also had a higher wt% of complement factors (e.g., C3, C4A, and C1q) in their coronas 
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than SE-NPs. The higher abundance of opsonins, such as complement factors and fibrinogen, 
on the PE-NPs than the SE-NPs is important because the presence of opsonins on the NPs’ 
surfaces could reduce their circulation time in vivo, and increase their uptake by immune 
cells.18,48–53 
Our finding that the uptake of PE-NPs by macrophages is higher than that of SE-NPs is 
likely due to the higher abundance of opsonins in the hard coronas of the PE-NPs. For instance, 
fibrinogen in the protein corona might bind to complement receptor type 3 (CR3), also known as 
the Mac-1 receptor,54,55 which would enhance NP phagocytosis. The presence of Mac-1 
receptors on RAW 264.7 macrophage cells,56 but not NIH 3T3 fibroblast cells, may explain why 
the macrophages internalized more PE-NPs than SE-NPs, whereas there was no significant 
difference in the uptake of PE-NPs and SE-NPs by NIH 3T3 fibroblasts. Overall, these findings 
demonstrate that the use of serum versus plasma as a mimic of exposure to the blood stream 
has a greater effect on NP uptake by immune cells than non-immune cells. This is consistent 
with the previous observation that different cell types may have different responses to the same 
NPs due to their specialized defense mechanisms,57 which may result in different levels of NP 
uptake. 
3.5 Conclusions 
In summary, this study showed that incubation of NPs with human serum or human plasma 
results in the formation of protein coronas that elicit different cell responses, namely NP uptake, 
due to their different compositions. The difference in cellular response to SE-NPs versus PE-
NPs was more significant for immune cells, which would likely affect the NPs’ blood circulation 
time, a crucial factor for NP targeting efficacy. Human plasma mimics the composition of the 
blood environment more accurately than human serum, so the use of plasma, and not serum, is 
essential for in vitro analysis of the protein corona. Such studies could improve the applicability 
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of in vitro data for predicting NP–protein interactions in vivo and developing more efficient NP-
based drug delivery systems for disease treatment. 
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3.7 Figures and Tables 
Table 3.1. Characterization of NPs that were exposed to human serum and human plasma. 
Average diameter of each type of NP was determined by both SEM and DLS. Total protein 
bound to the NPs was measured with a BCA protein assay, where the average and standard 
deviation was calculated from three replicates. 
Type of NPs d, SEM (nm) d, DLS (nm) Polydispersity 
Index 
ζ-potential 
(mV) 
Bound Proteins 
(μg/mg NPs) 
Pristine NPs 94.5 ± 15.7 104.9 ± 1.5 0.058 -13.56 ± 1.12 - 
SE-NPs 105.7 ± 13.7 134.9 ± 2.0 0.313 -6.95 ± 1.16 21 ± 2 
PE-NPs 110.5 ± 14.0 171.0 ± 2.4 0.346 -8.34 ± 1.23 30 ± 3 
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Figure 3.1. SEM images and size distribution histograms of pristine NPs (A), SE-NPs (B), and 
PE-NPs (C). Scale bar is 500 nm. Each histogram shows the size distribution of 50 NPs. 
Comparison of the histograms indicates protein corona formation increased the NPs’ diameters. 
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Figure 3.2. SDS-PAGE gel for NPs that were exposed to solutions containing 55% human 
serum or human plasma in PBS (A). The stars designate the protein bands that notably differ 
between SE-NPs and PE-NPs. Bar graph shows the molecular weight distribution of the corona 
proteins on the SE-NPs and PE-NPs, where the intensities of the protein bands within the 
indicated molecular weight ranges were quantified with Image J software (B). Results are mean 
± s.e.m., n = 3; asterisks (*) and (***) indicate P ≤ 0.05 and P ≤ 0.001, respectively. This shows 
that the biological milieu (serum or plasma solution) may significantly affect the hard corona 
composition. 
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Table 3.2. Ten most abundant proteins in the coronas of serum and plasma exposed NPs that 
were identified by LC–MS/MS. 
Plasma exposed NPs (PE-NPs) Serum exposed NPs (SE-NPs) 
Apolipoprotein E Apolipoprotein A1 chain A 
Apolipoprotein E chain A Proapolipoprotein 
Alpha fibrinogen Lipoprotein Gln 1 
Apolipoprotein C3 chain A Apolipoprotein E 
Fibrinogen chain A Apolipoprotein A4 
Apolipoprotein B100 Apolipoprotein E3 chain A 
Gelsolin Apolipoprotein E chain A 
Tetranectin Apolipoprotein C1 chain A 
Kininogen-1 Apolipoprotein B100 
Serum albumin Histidine-rich glycoprotein 
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Table 3.3. Complete list of proteins that were identified in the corona of PE-NPs by LC-MS/MS. 
The 10 most abundant proteins in the corona are italicized and underlined. 
 Accession Wt % Description 
Lipoproteins 
gi|178853 33.18 Apolipoprotein E  
gi|157831790 12.28 Chain A, common mutants of apolipoprotein E 
gi|186972736 5.30 Chain A, apolipoprotein C-III 
gi|306569733 3.10 Mutant apolipoprotein B 100  
gi|178775 1.03 Proapolipoprotein, partial  
gi|14277770 0.87 Chain A, apolipoprotein C-II  
gi|178855 0.59 Apolipoprotein J precursor  
gi|6103597 0.32 Apolipoprotein(a)  
gi|619383 0.30 Apolipoprotein D 
gi|12232634 0.29 Apolipoprotein L-I  
gi|178757 0.29 Apolipoprotein A-IV precursor  
gi|229479 0.29 Lipoprotein Gln I 
Coagulation 
gi|182424 8.30 Alpha-fibrinogen precursor  
gi|237823914 5.20 Chain A, fibrinogen 
gi|4504893 1.33 Kininogen-1 isoform 2 precursor  
gi|4503011 0.93 Carboxypeptidase N catalytic chain precursor 
gi|387031 0.91 Plasminogen, partial  
gi|125184 0.90 Plasma kallikrein 
gi|17426607 0.86 Coagulation factor V jinjiang B domain  
gi|4504489 0.60 Histidine-rich glycoprotein precursor  
gi|182439 0.59 Fibrinogen gamma chain  
gi|182430 0.59 Beta-fibrinogen precursor, partial  
gi|183910 0.58 Heparin cofactor II precursor  
gi|180352 0.58 Coagulation factor XI  
gi|180550 0.29 Plasma serine protease inhibitor precursor 
gi|4758502 0.28 Hyaluronan-binding protein 2 isoform 1 preproprotein 
Complement 
gi|179665 0.83 Complement component C3  
gi|179674 0.61 Complement component C4A  
gi|573114 0.30 C1q B-chain precursor  
gi|179726 0.28 C9 complement protein, partial  
gi|291922 0.27 Complement factor B  
Other 
components 
gi|4504165 2.33 Gelsolin isoform a precursor  
gi|156627579 1.62 Tetranectin precursor  
gi|28592 1.23 Serum albumin  
gi|183116 1.00 Insulin-like growth factor-binding protein  
gi|642908 0.94 Procollagen C-proteinase enhancer protein 
gi|33989 0.90 Inter-alpha-trypsin inhibitor heavy chain ITIH1  
gi|4504383 0.89 Hepatocyte growth factor activator preproprotein 
gi|10834982 0.64 Insulin-like growth factor-binding protein 5 precursor  
gi|1483187 0.59 
Inter-alpha-trypsin inhibitor family heavy chain-related 
protein (IHRP)  
gi|1082300 0.58 Collagen alpha 1(XVIII) chain  
gi|33985 0.54 Trypsin inhibitor  
gi|31397 0.32 Fibronectin precursor  
gi|28549 0.32 Alpha globin  
gi|259352 0.31 Serum amyloid A  
gi|34783164 0.30 Selenoprotein P, plasma, 1  
gi|112910 0.30 Alpha-2-HS-glycoprotein 
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Table 3.3 (cont.)      
Other 
components 
(cont.) 
gi|2104968 0.28 Chondroadherin 
Unidentified 
gi|189065306 1.62 Unnamed protein product  
gi|1572721 1.15 Megakaryocyte stimulating factor  
gi|36573 0.93 Unnamed protein product  
gi|553734 0.57 Putative  
gi|4506427 0.31 Retinoic acid receptor responder protein 2 precursor  
gi|27734883 0.28 Probable E3 ubiquitin-protein ligase TRIML2  
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Table 3.4. Complete list of proteins that were identified in the corona of SE-NPs by LC-MS/MS. 
The 10 most abundant proteins in the corona are italicized and underlined. 
 Accession Wt % Description 
Lipoproteins 
gi|157831262 38.48 Chain A, apolipoprotein A-I  
gi|178775 14.62 Proapolipoprotein, partial  
gi|229479 9.41 Lipoprotein Gln I 
gi|178853 7.67 Apolipoprotein E 
gi|178757 6.65 Apolipoprotein A-IV precursor  
gi|157832105 6.54 Chain A, apolipoprotein E3  
gi|157831790 3.56 Chain A, common mutants of apolipoprotein E 
gi|157831482 2.25 Chain A, apolipoprotein C-I 
gi|28780 1.51 Apolipoprotein B100 precursor  
gi|1480096 0.67 Apolipoprotein E3  
gi|4502161 0.65 Apolipoprotein C-IV precursor  
gi|619383 0.53 Apolipoprotein D  
gi|178741 0.17 Apolipoprotein C-II, partial  
gi|521205 0.17 Apolipoprotein C-III  
gi|12232634 0.15 Apolipoprotein L-I  
gi|119567981 0.13 Lipoprotein, Lp(a)  
Coagulation 
gi|4504489 1.28 Histidine-rich glycoprotein precursor  
gi|182424 0.82 Alpha-fibrinogen precursor  
gi|125184 0.47 Plasma kallikrein 
gi|190026 0.30 Plasminogen  
gi|180357 0.15 Coagulation factor XII  
gi|493792 0.15 Chain H, hirulog 3-thrombin complex  
gi|4504893 0.14 Kininogen-1 isoform 2 precursor  
gi|180352 0.14 Coagulation factor XI  
Complement 
gi|179674 0.31 Complement component C4A  
gi|179665 0.30 Complement component C3  
Other 
components 
gi|259352 0.37 Serum amyloid A  
gi|10834982 0.32 Insulin-like growth factor-binding protein 5 precursor  
gi|1483187 0.30 
Inter-alpha-trypsin inhibitor family heavy chain-related 
protein (IHRP)  
gi|4504383 0.30 Hepatocyte growth factor activator preproprotein  
gi|5031635 0.16 Cofilin-1  
gi|307141 0.16 Lysozyme precursor (EC 3.2.1.17)  
gi|183116 0.14 Insulin-like growth factor-binding protein  
gi|34783164 0.14 Selenoprotein P, plasma, 1  
Unidentified 
gi|36575 0.30 Unnamed protein product  
gi|1572721 0.30 Megakaryocyte stimulating factor  
gi|29446 0.16 Unnamed protein product  
gi|260436922 0.14 Suprabasin isoform 1 precursor  
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Figure 3.3. Classification of identified proteins in the NPs’ hard coronas with respect to their 
function in the blood. 
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Figure 3.4. Flow cytometry results for analysis of NP uptake by RAW 264.7 cells (A). Bar graph 
shows the median fluorescence intensities of NP-treated cells normalized to the median 
fluorescence of untreated cells (B). Results are mean ± s.e.m., n = 3; asterisk indicate P ≤ 0.05. 
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Figure 3.5. Confocal microscope images of RAW 264.7 cells incubated with SE-NPs (A) and 
PE-NPs (B). The scale bar is 20 μm. Confocal microscopy images show that uptake of the PE-
NPs by RAW 264.7 macrophage cells was higher than that of the SE-NPs. 
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Figure 3.6. Flow cytometry results for analysis of NP uptake by NIH 3T3 cells (A). Bar graph 
shows the median fluorescence intensities of NP-treated cells normalized to the median 
fluorescence of untreated cells (B). Results are mean ± s.e.m., n = 3. 
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Figure 3.7. Confocal microscopy images of NIH 3T3 fibroblast cells incubated with SE-NPs (A) 
and PE-NPs (B). Scale bar is 20 μm. Very little uptake was detected for either the SE-NPs or 
PE-NPs. 
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CHAPTER 4 
VISUALIZING INTRA-POPULATION CELL HETEROGENEITY WITH UNSUPERVISED SELF-
ORGANIZING MAPS OF SECONDARY ION MASS SPECTROMETRY DATA 
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4.1 Introduction 
The ability to direct hematopoietic stem cells (HSCs) to differentiate into a specific blood or 
immune cell lineage would enable the in vitro expansion of desired hematopoietic cell 
populations for the treatment of hematopoietic pathologies.2 Consequently, much research has 
focused on identifying the combinations of extrinsic cues that induce HSC self-renewal or 
differentiation into a specific lineage.  The multitude of factors combined with the scarcity of 
HSCs, <0.005% of bone marrow3 has stimulated the development of high-throughput 
microculture platforms4 that minimize the number of rare HSCs that are required to screen the 
effects of multiple cues on HSC fate.5–7 Yet, the small scale that makes these platforms so 
advantageous also introduces a new issue that must be addressed: intra-population 
heterogeneity. Namely, individual hematopoietic stem and progenitor cell (HSPC) populations 
exhibit cell-to-cell variability that affects their differentiation potential.8 Knowledge of this 
heterogeneity is required in order to design high-throughput screening platforms such that they 
contain enough cells to recreate the correct range of cell fate decisions.  
The Kraft lab has previously established that information about lineage-related surface 
chemistries can be acquired with time-of-flight secondary ion mass spectrometry (TOF-SIMS) or 
Raman spectroscopy and exploited to identify the differentiation states of individual 
hematopoietic cells isolated from mouse bone marrow.1,9,10 The cell spectra acquired by these 
two techniques encode for the biomolecules, such as amino acids and lipids at different locations 
on the cell, where TOF-SIMS detects biomolecules on the cell surface, and Raman spectroscopy 
detects biomolecules on and within the cell. In one publication that describes this work, 
hematopoietic cells at three distinct stages of B cell lymphopoiesis were studied: hematopoietic 
stem and progenitor cells (HSPCs: Lin-Sca1+cKit+), common lymphoid progenitors (CLPs; Lin-IL-
7R+Sca-1medc-Kitmed), and mature B cells (B220+IgM+). The differentiation stages of individual 
HCs could be identified by using a partial least-squares discriminant analysis (PLS-DA) model 
99 
 
 
that was constructed from TOF-SIMS data of hematopoietic cells of known differentiation stage.1 
While PLS-DA of single cell spectra provides a general framework to quantify the probability that 
an individual hematopoietic cell belongs to a specified cell population, information about the cell-
to-cell heterogeneity between and within population is not easily acquired with PLS-DA.  
Here, we explore an alternative multivariate analysis technique, called Self Organizing Maps 
(SOMs),11 for visualizing the cell-to-cell heterogeneity between and within related cell 
populations.  A SOM consists of an array of map units, where each map unit represents a range 
of variables (i.e., mass peak intensities) that are similar to the samples assigned to that map 
unit. The map units are arranged so that they are adjacent to the map units that have the most 
similar variables. The degree of similarity between neighboring map units, and thus the samples 
assigned to the map units, is encoded in the Unified Distance Matrix (U-Matrix) plot, where low 
values indicate little difference (high similarity) between a map unit and its neighbors. We show 
that SOMs of the previously reported TOF-SIMS data that was acquired from individual HSPCs, 
CLPs, and B cells enable visualizing the extent of heterogeneity between cells from these three 
hematopoietic cell populations.   
4.2 Methods  
4.2.1 Data sets  
Previously reported TOF-SIMS data of individual primary hematopoietic cells that were 
isolated from the bone marrow of young (2-4 months old) and old (10 months old) mice was 
used in this study.1 Three hematopoietic cell  populations were employed: 1) hematopoietic 
stem and progenitor cells (HSPCs) that do not express lineage antigens (Lin-) but that do 
express Sca1 and cKit (Lin-Sca-1+c-Kit+, LSK); 2) common lymphoid progenitors (CLPs, Lin-IL-
7Rα+Sca-1medc-Kitmed); and 3) mature B cells (B220+IgM+). These cells were isolated via flow 
cytometry, prepared, and analyzed with TOF-SIMS as previously described.1 The data sets 
consisted of only the mass peaks between 50 and 300 m/z because peaks with m/z below this 
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range are not chemically specific, and those above 300 m/z were not reproducibly detected with 
our instrumentation. Furthermore, each spectra contained only the peaks that are produced by 
either the most common lipid species12 or amino acids,13 but not those associated with common 
surface contaminants (m/z 73, 133, 147, 207, 221, and 281).1,14 This cell-related peak set was 
employed to minimize the possibility that the subsequent analyses were biased by contaminant 
molecules.  
These filtered spectra were used to create five data sets that were used in the subsequent 
analyses. These data sets consisted of spectra acquired from (1) hematopoietic cells harvested 
from old mice; (2) hematopoietic cells harvested from young mice; (3) HSPCs harvested from 
young and old mice; (4) CLPs harvested from young and old mice; and (5) B cells harvested 
from young and old mice.   
4.2.2 Principal component analysis  
PCA was performed using PLS Toolbox (v.6.7.1 Eigenvector Research, Manson, WA) run 
in MATLAB (v.7.14.0.739 R2012a, MathWorks Inc., Natick, MA). Each peak in a single 
spectrum was normalized to the total intensity of the cell-related peaks and autoscaled prior to 
PCA. 
4.2.3 Self organizing map 
SOM was performed on the normalized and autoscaled cell-related data sets using the 
SOM Toolbox (v.2.0. http://www.cis.hut.fi/projects/somtoolbox/download) run in MATLAB 
(v.7.11.0.584 R2010b, MathWorks Inc., Natick, MA). Prior to SOM analysis, each peak in a 
single spectrum was normalized to the total intensity of the cell-related peaks, and variance and 
mean for each mass peak were set to one and zero, respectively. The results are illustrated with 
hit histogram and U-Matrix maps. The hit histogram consists of an array of map units, where the 
number of samples designated to each map unit is shown, and every map unit represents the 
mass peak intensities that are similar to all cell samples assigned to that map unit. The U-matrix 
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shows the precise degree of similarity between the map units, where low U-matrix values 
indicate little difference (high similarity) between a map unit and its neighbors.  All the variables 
for map construction, initialization, and training process were selected and defined automatically 
by the SOM Toolbox.  
4.3 Results 
4.3.1 Extent of heterogeneity between individual HSPCs, CLPs, and B cells from young 
mice  
A SOM was constructed of the TOF-SIMS data acquired from 20 B cells, 20 CLPs, and 14 
HSPCs that were harvested from the bone marrow of young (2 to 4-month-old) mice. Our 
analysis was restricted to only the mass peaks that are known to be produced by amino acids13 
and phosphatidylycholine lipids,12 but not common surface contamination.14 This cell-related 
data set helps to ensure that the relationships between the cells revealed by SOM were based 
on cell surface biochemistries.  
The multi-population and individual hit histograms for the B cells, CLPs, and HSPCs, and 
the corresponding U-Matrix are shown in Figure 4.1. The number of samples that were assigned 
to each map unit for B cells, CLPs, or HSPCs are shown in red, green, and blue, respectively, 
on the hit histograms (Fig. 4.1A-D). Because each map unit represents a characteristic set of 
mass peak intensities, the cells assigned to the same map unit have similar surface chemistries, 
and thus, are expected to be from the same population. Consistent with this expectation, most 
map units contain only one cell type. However, one HSPC was assigned to the same map unit 
as a B cell. Because HSPCs and B cells are the most primitive and differentiated populations, 
respectively, in the B lymphocyte differentiation pathway, the placement of a HSPC and B cell 
on the same map unit suggests they share similar surface biochemistries despite their different 
phenotypes. 
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The extent of the surface biochemistry differences between individual hematopoietic cells from 
the same and different populations are encoded in the distances between the cells on the hit 
histogram, and the dissimilarities between map units, which are shown on the U-matrix (Fig. 
4.1E). With the exception of the one B cell and HSPC that are placed in the same map unit, 
each of the three hematopoietic cell populations are clustered at different, non-overlapping 
locations on the map. Specifically, the B cells occupy the top map units, the CLPs are on the 
bottom units, and the HSPCs are clustered on the center left map units. Furthermore, the yellow 
and orange hexagons in the fourth row from the top of the U matrix represents high distances, 
and thus, a high degree of dissimilarity, between the map units occupied by the clustered 
HSPCs and those occupied by the B cells. This indicates that the surface chemistries of the 
individual HSPCs and B cells are generally more similar to other HSPCs and B cells, 
respectively, than they are to cells from other populations. Similarly, the clustering of the CLPs 
at distinct map locations that do not overlap with the B cells or HSPCs implies less variance in 
cell surface biochemistry between individual CLPs than between CLPs and B cells or HSPCs. 
However, the CLPs are less tightly clustered and have higher U-Matrix values than the B cells 
and HSPCs, indicating the CLPs have higher intra-population variation in their surface 
chemistries than the HSPC or B cell populations.    
4.3.2 Extent of heterogeneity between individual HSPCs, CLPs, and B cells from old mice  
Although hematopoietic stem cells from young and old mice express the same 
differentiation stage-associated cell surface antigens, they exhibit significant differences in 
function. Therefore, we investigated whether hematopoietic cells harvested from old mice 
exhibited the same levels of cell-to-cell variation. A SOM model was constructed from the TOF-
SIMS data acquired from 30 B cells, 25 CLPs, and 29 HSPCs isolated from five relatively old 
(10-month-old) mice (Fig. 4.2). As noted above, the localization of both B cells and HSPCs on a 
single map unit (i.e., middle right of hit histograms, Fig. 4.2B,D) likely indicates these cells share 
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similar surface chemistries in spite of their distinctly different functions. However, because 
HSPCs must differentiate into CLPs, the localization of both HSPCs and CLPs on the same 
map unit (i.e., top left and bottom right corners in Figure 4.2C, D) may suggest that these 
HSPCs are in the process of differentiating into CLPs. 
In this SOM model of the cells from old mice, the B cells are more tightly clustered on the hit 
histogram than the CLPs and HSPCs. This suggests that the surface chemistries of the B cells 
are more homogeneous than those of the CLP and HSPC populations. This suggestion is 
confirmed by the low U-Matrix values (Fig. 4.2E) for the map units occupied by the B cells. In 
comparison, the map units occupied by the CLPs and HSPCs have higher U-Matrix values, and 
thus, these cell populations have higher within-population variability. Thus, our data suggests 
the CLP population is more heterogeneous than B cells and HSPCs regardless of the age of the 
donor organism. However, the HSPC population seems to become more heterogeneous as the 
age of the organism increases. 
Noteworthy, the heterogeneity between and within the HSPC, CLP, and B cell populations is 
more easily visualized in two dimensions with SOM than the more popular multivariate analysis 
technique, principal component analysis (PCA). PCA reduces the spectra into orthogonal 
principal components (PCs), which are the linear combinations of variables that capture the 
maximum variation between each sample. A two-dimensional PCA model of the TOF-SIMS data 
of the cells obtained from old mice is shown in Figure 4.3. The first two principal components 
(PC 1 and PC 2) captured more than 41% of variation within cell-related mass peaks. However, 
it is essential to capture all the spectral variance in the data set in order to assess the sample-
to-sample variation. Therefore, more PCs are needed to be included in the model, which would 
add one more dimension to the plot for each PC. This would generate plots with three or more 
dimensions. Because it is not possible to visualize more than three dimensions, and thus three 
PCs in a single plot, multiple graphs would be required, which would make data interpretation 
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difficult and inconvenient. In contrast, the SOM considers all of the variables, mass peaks in our 
case, to generate a 2D plot that captures all of the sample variance. Thereby, SOM facilitates 
visualizing and interpreting the variance within samples of complex data sets, such as TOF-
SIMS data.     
4.3.3 Visualization of the age-related heterogeneity within hematopoietic cell populations  
In addition to the variations in surface chemistry that were indicative of the different HC 
populations, we previously identified age-related variations in cell surface chemistry within each 
hematopoietic cells population.1 To visualize the extent of this age-related intra-population 
variation, a separate SOM model was developed for each HC population using the spectra 
acquired from cells that were harvested from 10-month-old (old) and 2- to 4-month-old (young) 
C57BL/6 mice. The resulting hit histograms for the B cells, CLPs, and HSPCs are shown in 
Figure 4.4. The B cells from the young and old mice are weakly separated, where the B cells 
from the old mice are slightly more abundant on the left side of the hit histogram, and those from 
the young mice favor the right side (Fig. 4.4A). This weak separation suggests that the age-
related variations in surface chemistry within the B cell population are small. In contrast, the hit 
histograms from the SOM models of the CLP and HSPC populations show distinct separation 
between the cells from the young and old mice (Fig. 4.4B,C). This indicates that the surface 
chemistry varies significantly within the CLP and HSPC populations due to the age of the host 
organism (Fig. 4.4B,C).  
4.4 Discussion and Conclusion 
Cell to cell heterogeneity within hematopoietic cell populations ranging from the most 
primitive HSCs15 to differentiated macrophages16 is biologically relevant, and may be required to 
produce the bioactivities that are attributed to the population as a whole.17  The necessity for 
such intra-population heterogeneity has serious implications on the expansion of HSPCs in 
culture for both mechanistic studies as well as therapeutic use.17  For example, small stem or 
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progenitor cell cultures may not contain enough cells from each subtypes to produce the range 
of fate decisions that are required to re-create the population’s function. Conversely, large-scale 
expansion is likely to produce a population with high proliferative activity at the expense of less 
proliferative, but functionally essential subtypes.17 Knowledge of this heterogeneity is also 
essential for the design of artificial culture systems that contain the minimum number of cells to 
mimic HSC homeostasis, as well as for interpreting the effects of stimuli (i.e., matrix stiffness) 
on the small number of HSCs located at distinct regions of a microscale biomaterial culture. 
Thus, we aim to explore if it is possible to utilize SOM technique for analysis of TOF-SIMS data 
acquired from HC subpopulation, and obtain more information about the heterogeneity within 
these cells.  
PCA is frequently used for multivariate data analysis in various fields. It could effectively 
reduce the dimensions of large data sets by generating linear combinations of original variables 
which could make data analysis more convenient. However, more than two principal 
components, linear combinations of variables, are often required to capture the majority of 
spectral variation in the data set, which adversely affects data visualization.18–20 This 
necessitates the usage of multiple 2D or 3D plots in order to visualize and capture the trends 
within the data. Therefore, applying other multivariate analysis methods, such as SOM, could 
help to prevent these complexities in data visualization and analysis. Here, we demonstrated 
that SOM models could generate 2D plots that are easier to interpret the data, and visualize the 
heterogeneity within different HC subpopulations. Each HC subpopulation, B cells, CLPS, and 
HSPCS were located at distinct locations on the 2D map, and hit histograms and U-Matrices 
were used to obtain more information about cell-to-cell heterogeneity. Therefore, constructing 
SOM models for the multivariate analysis of complex data sets that cannot be compressed into 
a single 2D plot with PCA is an effective practical approach for visualizing variations between 
samples.                      
106 
 
 
4.5 References 
(1)  Frisz, J. F.; Choi, J. S.; Wilson, R. L.; Harley, B. A. C.; Kraft, M. L. Identifying 
Differentiation Stage of Individual Primary Hematopoietic Cells from Mouse Bone Marrow 
by Multivariate Analysis of TOF-Secondary Ion Mass Spectrometry Data. Anal. Chem. 
2012, 84 (10), 4307–4313. 
(2)  Daley, G. Q.; Scadden, D. T. Prospects for Stem Cell-Based Therapy. Cell 2008, 132 (4), 
544–548. 
(3)  Kiel, M. J.; Yilmaz, Ö. H.; Iwashita, T.; Yilmaz, O. H.; Terhorst, C.; Morrison, S. J. SLAM 
Family Receptors Distinguish Hematopoietic Stem and Progenitor Cells and Reveal 
Endothelial Niches for Stem Cells. Cell 2005, 121 (7), 1109–1121. 
(4)  Ranga, A.; Lutolf, M. P. High-Throughput Approaches for the Analysis of Extrinsic 
Regulators of Stem Cell Fate. Curr. Opin. Cell Biol. 2012, 24 (2), 236–244. 
(5)  Martin, T. A.; Caliari, S. R.; Williford, P. D.; Harley, B. A.; Bailey, R. C. The Generation of 
Biomolecular Patterns in Highly Porous Collagen-GAG Scaffolds Using Direct 
Photolithography. Biomaterials 2011, 32 (16), 3949–3957. 
(6)  Mei, Y.; Saha, K.; Bogatyrev, S. R.; Yang, J.; Hook, A. L.; Kalcioglu, Z. I.; Cho, S.-W.; 
Mitalipova, M.; Pyzocha, N.; Rojas, F.; et al. Combinatorial Development of Biomaterials 
for Clonal Growth of Human Pluripotent Stem Cells. Nat. Mater. 2010, 9 (9), 768–778. 
(7)  Luo, W.; Yousaf, M. N. Tissue Morphing Control on Dynamic Gradient Surfaces. J. Am. 
Chem. Soc. 2011, 133 (28), 10780–10783. 
(8)  Chang, H. H.; Hemberg, M.; Barahona, M.; Ingber, D. E.; Huang, S. Transcriptome-Wide 
Noise Controls Lineage Choice in Mammalian Progenitor Cells. Nature 2008, 453 (7194), 
544–547. 
107 
 
 
(9)  Ilin, Y.; Choi, J. S.; Harley, B. A. C.; Kraft, M. L. Identifying States along the 
Hematopoietic Stem Cell Differentiation Hierarchy with Single Cell Specificity via Raman 
Spectroscopy. Anal. Chem. 2015, 87 (22), 11317–11324. 
(10)  Ilin, Y.; Kraft, M. L. Secondary Ion Mass Spectrometry and Raman Spectroscopy for 
Tissue Engineering Applications. Curr. Opin. Biotechnol. 2015, 31, 108–116. 
(11)  Kohonen, T. Self-Organizing Maps; Huang, T. S., Kohonen, T., Schroeder, M. R., Series 
Eds.; Springer Series in Information Sciences; Springer Berlin Heidelberg: Berlin, 
Heidelberg, 2001; Vol. 30. 
(12)  Anderton, C. R.; Vaezian, B.; Lou, K.; Frisz, J. F.; Kraft, M. L. Identification of a Lipid-
Related Peak Set to Enhance the Interpretation of TOF-SIMS Data from Model and 
Cellular Membranes. Surf. Interface Anal. 2012, 44 (3), 322–333. 
(13)  Kulp, K. S.; Berman, E. S. F.; Knize, M. G.; Shattuck, D. L.; Nelson, E. J.; Wu, L.; 
Montgomery, J. L.; Felton, J. S.; Wu, K. J. Chemical and Biological Differentiation of 
Three Human Breast Cancer Cell Types Using Time-of-Flight Secondary Ion Mass 
Spectrometry. Anal. Chem. 2006, 78 (11), 3651–3658. 
(14)  Oran, U.; Ünveren, E.; Wirth, T.; Unger, W. E. S. Poly-Dimethyl-Siloxane (PDMS) 
Contamination of Polystyrene (PS) Oligomers Samples: A Comparison of Time-of-Flight 
Static Secondary Ion Mass Spectrometry (TOF-SSIMS) and X-Ray Photoelectron 
Spectroscopy (XPS) Results. Appl. Surf. Sci. 2004, 227 (1–4), 318–324. 
(15)  Schroeder, T. Hematopoietic Stem Cell Heterogeneity: Subtypes, Not Unpredictable 
Behavior. Cell Stem Cell 2010, 6 (3), 203–207. 
(16)  Galli, S. J.; Borregaard, N.; Wynn, T. A. Phenotypic and Functional Plasticity of Cells of 
Innate Immunity: Macrophages, Mast Cells and Neutrophils. Nat. Immunol. 2011, 12 (11), 
1035–1044. 
108 
 
 
(17)  Phinney, D. G. Functional Heterogeneity of Mesenchymal Stem Cells: Implications for 
Cell Therapy. J. Cell. Biochem. 2012, 113 (9), 2806–2812. 
(18)  Annas, S.; Kanai, T.; Koyama, S. Principal Component Analysis and Self-Organizing Map 
for Visualizing and Classifying Fire Risks in Forest Regions. Agric. Inf. Res. 2007, 16 (2), 
44–51. 
(19)  Laitinen, N.; Rantanen, J.; Laine, S.; Antikainen, O.; Räsänen, E.; Airaksinen, S.; Yliruusi, 
J. Visualization of Particle Size and Shape Distributions Using Self-Organizing Maps. 
Chemom. Intell. Lab. Syst. 2002, 62 (1), 47–60. 
(20)  Lloyd, G. R.; Brereton, R. G.; Duncan, J. C. Self Organising Maps for Distinguishing 
Polymer Groups Using Thermal Response Curves Obtained by Dynamic Mechanical 
Analysis. Analyst 2008, 133 (8), 1046–1059. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
109 
 
 
4.6 Figures 
 
Figure 4.1. Overlaid hit histogram (A), hit histograms for B cells (B), CLPs (C), HSPCs (D) from 
young mice, and U-Matrix (E). 
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Figure 4.2. Overlaid hit histogram (A), hit histograms for B cells (B), CLPs (C), HSPCs (D) from 
old mice, and U-Matrix (E). 
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Figure 4.3. PCA model constructed for HCs derived from old mice including 30 B cells, 25 
CLPs, and 29 HSPCs. 
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Figure 4.4. Hit histograms and U-Matrices obtained from SOM models constructed for B cells, 
CLPs, and HSPCs derived from old and young mice. 
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CHAPTER 5 
CONCLUSION AND FUTURE OBJECTIVES  
5.1 Conclusion 
When NPs enter into the biological environment that contains proteins and other 
biomolecules, these species bind to the NPs’ surfaces and form the protein corona. Previous 
works that focused on exploring the effect of the protein corona on the targeting efficiency of 
functionalized NPs showed that the adsorbed proteins covered the targeting ligands on the NPs 
and prevented them from binding to their targets.1,2 To overcome this problem, we investigated 
the feasibility of utilizing the proteins in the corona themselves as the targeting ligands for the 
selective delivery of NPs to the desired cells. As a model for this targeting approach, we aimed 
to enrich the protein corona with immunoglobulins, and then assessed whether the opsonin-
enriched corona was capable of targeting the NPs to RAW 264.7 macrophage immune cells. 
For this purpose, we pre-coated silica NPs with gamma-globulins prior to exposing them to 
human plasma for protein corona formation. Analysis of protein corona composition showed that 
the protein corona of gamma-globulin pre-coated NPs was enriched with immunoglobulins, as 
we expected. However, the cellular uptake of these NPs was not significantly different than 
control NPs that did not have any immunoglobulins in their corona. Furthermore, our analysis 
indicated that these immunoglobulins could not bind to their target biomolecules because they 
were masked by other plasma proteins adsorbed onto the NPs. Thus, in order to exploit the 
protein corona for targeted NP delivery, the desired targeting proteins must be recruited from 
the plasma to the protein corona and positioned such that they are accessible to their binding 
partners on the target cells. Therefore, future work should address the need for methods to 
control the spatial orientation of the proteins within the corona. This would help to develop a 
functional protein corona that could actively target NPs to the desirable cells and tissues within 
the body. 
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Various biological solutions may be used to form a protein corona in vitro for studies of how 
corona formation affects the NP’s physical properties and cell response. However, these 
biological mediums have different compositions that could significantly influence the results of 
these in vitro protein corona investigations. The work in Chapter 3 showed that the selection of 
the biological medium affects corona composition, the physical characteristics of the corona-
coated NPs (i.e., their size), and cellular uptake. Incubating NPs with human plasma and human 
serum produces protein coronas that have notably different compositions. NPs exposed to 
human plasma had higher fibrinogen and complement factors in their corona than NPs 
incubated with human serum. As a result of this opsonin-enrichment in the corona of plasma-
exposed NPs, these particles had higher uptake by macrophages than serum-exposed NPs. 
Because human plasma better imitates blood composition than human serum, using plasma, 
and not serum, would help to obtain more accurate information about NP-protein interactions. 
The preliminary information about how NPs interact with biological components obtained in vitro 
would help to design more efficient NP drug delivery systems in vivo.  
The self-organizing map (SOM) is a powerful multivariate data analysis technique to 
visualize complex data sets within a single 2D plot. Unlike other methods in which multiple 2D or 
3D plots are often needed to visualize the variation between samples, SOM provides 2D plots 
that are more easily interpreted for observation of the heterogeneity between samples. 
Therefore, we used this technique to identify the heterogeneity within and between three distinct 
hematopoietic cell (HC) lineages in B cell lymphopoiesis, namely mature B cells, common 
lymphoid progenitors (CLPs), and hematopoietic stem and progenitor cells (HSPCs). SOM 
models developed for the TOF-SIMS data that was acquired from HCs obtained from young and 
old mice indicated that fully differentiated B cells have less within-population variation than 
CLPs and HSPCs. In contrast, the CLPs exhibited more heterogeneity than the other two 
populations regardless of the age of the donor mice. This preliminary work suggests that the 
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SOM method could provide useful knowledge regarding the extent of variability within HC 
populations without the necessity of working with complex 3D or multiple 2D plots. This 
knowledge would facilitate the design of artificial HC culture platforms that recapitulate the 
variability, and thus function, of HC populations within the body.        
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